Canada has been increasingly urging citizens to get <a href="https://www.wionews.com/topics/coronavirus-vaccine">vaccinated</a> against the deadly coronavirus that has sent the country into repeated lockdowns. However, a Canadian soldier decided to go against the government.

Ladislas Kenderesi, a Canadian officer cadet, will be facing rare mutiny charges for allegedly urging his fellow soldiers to not help the Canadian government in the distribution of COVID-19 vaccines.

Also read |&nbsp;<a href="https://www.wionews.com/world/russia-linked-agency-hires-influencers-to-spread-fake-news-about-pfizer-vaccine-387419" hreflang="en">Russia-linked agency hires influencers to spread fake news about Pfizer vaccine</a>

The Department of National Defence has charged him with “endeavoring to persuade another person to join in a mutiny” and “behaving in a scandalous manner unbecoming of an officer”.

Kenderesi had appeared in an anti-lockdown rally in Toronto in his military uniform and urged people to not get tempted by the “killer” vaccines. He also asked his fellow mates to directly disobey orders of distributing vaccines in the country.

Also read |&nbsp;<a href="https://www.wionews.com/world/moderna-says-covid-vaccine-highly-effective-among-adolescents-aged-12-and-above-387313" hreflang="en">Moderna says Covid vaccine 'highly effective' among adolescents aged 12 and above</a>

“I’m asking the military, right now serving, truck drivers, medical, engineers, whatever you are, do not take this unlawful order in distribution of this vaccine,” he was heard preaching at the rally. “I might get in a lot of shit for doing this. But I don’t care any more.”

He was relieved of his duties on May 12, as soon as the officials got a hint about his appearance at the anti-lockdown rally.

If proven guilty, Kenderesi might face life imprisonment or five years behind the bars. Charges of mutiny are very rare in Canada as nobody has been charged for the past few decades.

Meanwhile, supporters of Kenderesi have started a crowdfunding campaign to raise the legal fees for him, although a court martial date is still pending for the officer.

Canada has been increasingly urging citizens to get vaccinated against the deadly coronavirus that has sent the country into repeated lockdowns. However, a Canadian soldier decided to go against the government.

Canada has been increasingly urging citizens to get vaccinated against the deadly coronavirus that has sent the country into repeated lockdowns. However, a Canadian soldier decided to go against the government. Ladislas Kenderesi, a Canadian officer cadet, will be facing rare mutiny charges for allegedly urging his fellow soldiers to not help the Canadian government in the distribution of COVID-19 vaccines. Also read | Russia-linked agency hires influencers to spread fake news about Pfizer vaccine The Department of National Defence has charged him with “endeavoring to persuade another person to join in a mutiny” and “behaving in a scandalous manner unbecoming of an officer”. Kenderesi had appeared in an anti-lockdown rally in Toronto in his military uniform and urged people to not get tempted by the “killer” vaccines. He also asked his fellow mates to directly disobey orders of distributing vaccines in the country. Also read | Moderna says Covid vaccine 'highly effective' among adolescents aged 12 and above “I’m asking the military, right now serving, truck drivers, medical, engineers, whatever you are, do not take this unlawful order in distribution of this vaccine,” he was heard preaching at the rally. “I might get in a lot of shit for doing this. But I don’t care any more.” He was relieved of his duties on May 12, as soon as the officials got a hint about his appearance at the anti-lockdown rally. If proven guilty, Kenderesi might face life imprisonment or five years behind the bars. Charges of mutiny are very rare in Canada as nobody has been charged for the past few decades. Meanwhile, supporters of Kenderesi have started a crowdfunding campaign to raise the legal fees for him, although a court martial date is still pending for the officer.

Canadian soldier charged with mutiny for blocking vaccine distribution

Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 50 million shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday.&nbsp;

While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson &amp; Johnson exporting its jabs from the US to other countries in the near future, the sources privy to discussions added.&nbsp;

Two rounds of high-level meetings chaired by the Cabinet Secretary were held last week on the availability of vaccines in the global as well as domestic markets as it was felt that there is an urgent need to procure the jabs at a time the country is reeling under an unprecedented second wave of COVID-19 and a widening gap between supply and requirement.&nbsp;

Currently, the country is using two 'Made in India' jabs, Covishield and Covaxin, to inoculate its billion-plus population and has administered numerous doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.&nbsp;

In the high-level meeting officials from the Ministry of External Affairs, NITI Aayog, Department of Biotechnology, Law Ministry and Health Ministry were present.&nbsp;

It was discussed that Moderna doesn't have surplus vaccines to share in 2021 and that it plans to launch its single-dose vaccine for the Indian market only in 2022, for which, they are in discussion with Cipla and other Indian companies, a source said.&nbsp;

It is learnt that Cipla has already evinced interest in procuring 50 million doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory requirements/policy regime. The Health Ministry has also been asked to take an early decision on Cipla's request regarding support required by them for procurement of Moderna vaccines.&nbsp;

In the case of Pfizer, the US pharma giant has indicated availability of 50 million vaccine doses, 10 million in July, 10 million in August, 20 million in September and 10 million in October, for supply to India in 2021 and that it will deal only with Government of India and payment for vaccines will have to be made by GOI to Pfizer India.&nbsp;

The central government will make its own arrangement for further channelization of procured vaccines in the domestic market.&nbsp;

According to another source, for the supply of vaccines to India, Pfizer has asked for indemnification from the Government of India and a document in this regard has been received from Pfizer Inc.&nbsp;

Further, Pfizer has also sought certain relaxations in the regulatory regime, including relaxation in the requirement of post-approval bridging trials and dispensing the requirement of testing their vaccines in CDL (Central Drugs Laboratory).&nbsp;

Taking into consideration the track record of the company, similar arrangements done with other countries in the world and the current pandemic situation, an overall view may be taken to indemnify the company by the government, officials said but flagged that in case a view is taken to indemnify the company, similar demands may be made by other companies.&nbsp;

As per the information furnished by Pfizer, around 116 countries in the world including the USA have signed the indemnification document.&nbsp;

Further, considering that over 14.7 crore doses of Pfizer had been administered worldwide without any significant reports of adverse effects, a view needs to be taken to indemnify the company in order to supplement the availability of vaccines in India, officials discussed at one recent meeting.&nbsp;

It was suggested that a decision on the issue of Pfizer Inc may be taken at the earliest and that NEGVAC (National Expert Group on Vaccine Administration for COVID-19) may hold a meeting immediately on these issues.&nbsp;

At a press conference on Monday, in response to a question on states being unable to procure vaccines directly from Moderna and Pfizer, Health Ministry Joint Secretary Lav Agarwal had said, "Whether it is Pfizer or Moderna, at the Centre-level, we have been coordinating with them."&nbsp;

"Also, the order book of both Pfizer and Moderna is full so it depends on their surplus that how much they can provide in India... They will come back to the Centre and we will help in facilitation to states," he said. &nbsp;&nbsp;

Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 50 million shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday.

Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 50 million shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday. While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future, the sources privy to discussions added. Two rounds of high-level meetings chaired by the Cabinet Secretary were held last week on the availability of vaccines in the global as well as domestic markets as it was felt that there is an urgent need to procure the jabs at a time the country is reeling under an unprecedented second wave of COVID-19 and a widening gap between supply and requirement. Currently, the country is using two 'Made in India' jabs, Covishield and Covaxin, to inoculate its billion-plus population and has administered numerous doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present. In the high-level meeting officials from the Ministry of External Affairs, NITI Aayog, Department of Biotechnology, Law Ministry and Health Ministry were present. It was discussed that Moderna doesn't have surplus vaccines to share in 2021 and that it plans to launch its single-dose vaccine for the Indian market only in 2022, for which, they are in discussion with Cipla and other Indian companies, a source said. It is learnt that Cipla has already evinced interest in procuring 50 million doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory requirements/policy regime. The Health Ministry has also been asked to take an early decision on Cipla's request regarding support required by them for procurement of Moderna vaccines. In the case of Pfizer, the US pharma giant has indicated availability of 50 million vaccine doses, 10 million in July, 10 million in August, 20 million in September and 10 million in October, for supply to India in 2021 and that it will deal only with Government of India and payment for vaccines will have to be made by GOI to Pfizer India. The central government will make its own arrangement for further channelization of procured vaccines in the domestic market. According to another source, for the supply of vaccines to India, Pfizer has asked for indemnification from the Government of India and a document in this regard has been received from Pfizer Inc. Further, Pfizer has also sought certain relaxations in the regulatory regime, including relaxation in the requirement of post-approval bridging trials and dispensing the requirement of testing their vaccines in CDL (Central Drugs Laboratory). Taking into consideration the track record of the company, similar arrangements done with other countries in the world and the current pandemic situation, an overall view may be taken to indemnify the company by the government, officials said but flagged that in case a view is taken to indemnify the company, similar demands may be made by other companies. As per the information furnished by Pfizer, around 116 countries in the world including the USA have signed the indemnification document. Further, considering that over 14.7 crore doses of Pfizer had been administered worldwide without any significant reports of adverse effects, a view needs to be taken to indemnify the company in order to supplement the availability of vaccines in India, officials discussed at one recent meeting. It was suggested that a decision on the issue of Pfizer Inc may be taken at the earliest and that NEGVAC (National Expert Group on Vaccine Administration for COVID-19) may hold a meeting immediately on these issues. At a press conference on Monday, in response to a question on states being unable to procure vaccines directly from Moderna and Pfizer, Health Ministry Joint Secretary Lav Agarwal had said, "Whether it is Pfizer or Moderna, at the Centre-level, we have been coordinating with them." "Also, the order book of both Pfizer and Moderna is full so it depends on their surplus that how much they can provide in India... They will come back to the Centre and we will help in facilitation to states," he said.

Moderna's single-dose vaccine in India likely next year; Pfizer ready with 50 mn doses for 2021

When the Indian government allowed states to pursue their own vaccine procurement, the idea was welcomed.

States governments were quick to seize the moment. Some chief ministers announced global tenders to buy shots from the international market. Weeks later, they are complaining again.

Because companies like Pfizer and Moderna don't want to deal with them. They want to negotiate directly with the centre and set the terms.&nbsp;

So what do these vaccine majors need from India?

It's not just about the money. They want the kind of guarantees that India hasn't given any vaccine maker.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-why-cant-india-get-covid-vaccines-from-pfizer-and-moderna-387165/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Pfizer and Moderna are among the best shots on the international market. Both vaccines work on the same technology. They are more than 90 per cent effective. Together, they have been approved by more than 40 countries. India wants them too. But on its own terms.

The government has authorised states to negotiate for themselves. Global tenders were announced. But it proved to be a damp squib as vaccine makers refused to deal with state governments.

Punjab made request to Moderna, it was denied. Moderna says it will only deal with the central government.

The Delhi state government wrote to Moderna, Pfizer and Johnson and Johnson. It got the same reply. They will only deal with the Government of India.&nbsp;

Beyond the obvious need of approvals and clearances, these vaccine companies have their own demands.

For instance, Pfizer CEO claims that they have been trying to get Pfizer vaccines to India for months. But Pfizer wants indemnity, a legal exemption from future lawsuits over their vaccines. Countries like the US and Britain have signed such clauses.

It basically means that if the vaccine maker is sued in India, it will be the government's problem, not the company's. India has not given such indemnity to any vaccine producer. Why should Pfizer be the exception?

The discussion is still on between the company and the government. In the past, Pfizer has been accused of bullying Latin American countries. They demanded embassy buildings and military bases as guarantee against the cost of any future legal cases.

The other problem is supply. Rich countries have already taken most of the shots off the shelves. Reports say, Moderna has its hands full with the existing orders. It might not have more doses for India. According to a report in April, Moderna already had orders to supply more than 1,000 million doses. These are for countries like the US, the EU, Canada, Japan, Switzerland and others.

Moderna is planning a major expansion in manufacturing. But even with a global tender, India may have to wait in line for its deliveries.

States like, Maharashtra, Uttar Pradesh, Tamil Nadu, Kerala and Karnataka have issued global tenders. But all of them are waiting for a bid.

When the Indian government allowed states to pursue their own vaccine procurement, the idea was welcomed. States governments were quick to seize the moment. Some chief ministers announced global tenders to buy shots from the international market.

When the Indian government allowed states to pursue their own vaccine procurement, the idea was welcomed. States governments were quick to seize the moment. Some chief ministers announced global tenders to buy shots from the international market. Weeks later, they are complaining again. Because companies like Pfizer and Moderna don't want to deal with them. They want to negotiate directly with the centre and set the terms. So what do these vaccine majors need from India? It's not just about the money. They want the kind of guarantees that India hasn't given any vaccine maker. × Pfizer and Moderna are among the best shots on the international market. Both vaccines work on the same technology. They are more than 90 per cent effective. Together, they have been approved by more than 40 countries. India wants them too. But on its own terms. The government has authorised states to negotiate for themselves. Global tenders were announced. But it proved to be a damp squib as vaccine makers refused to deal with state governments. Punjab made request to Moderna, it was denied. Moderna says it will only deal with the central government. The Delhi state government wrote to Moderna, Pfizer and Johnson and Johnson. It got the same reply. They will only deal with the Government of India. Beyond the obvious need of approvals and clearances, these vaccine companies have their own demands. For instance, Pfizer CEO claims that they have been trying to get Pfizer vaccines to India for months. But Pfizer wants indemnity, a legal exemption from future lawsuits over their vaccines. Countries like the US and Britain have signed such clauses. It basically means that if the vaccine maker is sued in India, it will be the government's problem, not the company's. India has not given such indemnity to any vaccine producer. Why should Pfizer be the exception? The discussion is still on between the company and the government. In the past, Pfizer has been accused of bullying Latin American countries. They demanded embassy buildings and military bases as guarantee against the cost of any future legal cases. The other problem is supply. Rich countries have already taken most of the shots off the shelves. Reports say, Moderna has its hands full with the existing orders. It might not have more doses for India. According to a report in April, Moderna already had orders to supply more than 1,000 million doses. These are for countries like the US, the EU, Canada, Japan, Switzerland and others. Moderna is planning a major expansion in manufacturing. But even with a global tender, India may have to wait in line for its deliveries. States like, Maharashtra, Uttar Pradesh, Tamil Nadu, Kerala and Karnataka have issued global tenders. But all of them are waiting for a bid.

Pfizer and Moderna don't want to deal with Indian states for vaccines

Hyderabad-based Bharat Biotech has summitted application to the World Health Organization for Emergency Use Listing (EUL) of its Covid vaccine Covaxin, becoming the second India-made vaccine to apply at the global body for authorisation.

Bharat Biotech had summitted its Expression of Interest (EOI) on April 19, with more information required according to documents on WHO website. &nbsp;

It will have to now go through three more stages, pre-submission meeting, dossier accepted for review and final status of assessment. The pre-submission meeting will take place later in May or June. &nbsp;&nbsp;

Last week, speaking to WION exclusively, Suchitra Ella, joint managing director, Bharat Biotech, said, the Covaxin "proved to be neutralising all variants including double mutant, which has been observed in India" and it has an 'edge' given it is inactivated virus vaccines produced in cell culture or vero cell platform.&nbsp;

The company plans to produce one billion vaccines via its three different facilities in three states, 200-250 million from Hyderabad facility, around 500 million doses from Bangalore and 200 million from Ankleshwar, Gujarat.&nbsp;

A benefit of WHO listing will allow Covaxin to get global approval for use, something that has other benefits like easy movement of Indians, who have been vaccinated by it. While when it comes to mutual recognition of vaccines by countries is still under progress, if and when it comes into effect, WHO approved vaccines will give an automatic benefit. &nbsp;

On February 15, WHO gave emergency use approval to Covishield vaccine produced by Serum Institute of India. So far, seven vaccines globally have been given approval by WHO for EUL, these are Pfizer's Comirnaty, Astrazeneca's AZD1222, Janssen's Ad26.COV2.S, Moderna's mRNA-1273 and Sinopharm's SARS-CoV-2 Vaccine. Russia's Sputnik, China's Sinovac and Cuba have also applied for emergency approval.&nbsp;

Hyderabad-based Bharat Biotech has summitted application to the World Health Organization for Emergency Use Listing (EUL) of its Covid vaccine Covaxin, becoming the second India-made vaccine to apply at the global body for authorisation.

Hyderabad-based Bharat Biotech has summitted application to the World Health Organization for Emergency Use Listing (EUL) of its Covid vaccine Covaxin, becoming the second India-made vaccine to apply at the global body for authorisation. Bharat Biotech had summitted its Expression of Interest (EOI) on April 19, with more information required according to documents on WHO website. It will have to now go through three more stages, pre-submission meeting, dossier accepted for review and final status of assessment. The pre-submission meeting will take place later in May or June. Last week, speaking to WION exclusively, Suchitra Ella, joint managing director, Bharat Biotech, said, the Covaxin "proved to be neutralising all variants including double mutant, which has been observed in India" and it has an 'edge' given it is inactivated virus vaccines produced in cell culture or vero cell platform. The company plans to produce one billion vaccines via its three different facilities in three states, 200-250 million from Hyderabad facility, around 500 million doses from Bangalore and 200 million from Ankleshwar, Gujarat. A benefit of WHO listing will allow Covaxin to get global approval for use, something that has other benefits like easy movement of Indians, who have been vaccinated by it. While when it comes to mutual recognition of vaccines by countries is still under progress, if and when it comes into effect, WHO approved vaccines will give an automatic benefit. On February 15, WHO gave emergency use approval to Covishield vaccine produced by Serum Institute of India. So far, seven vaccines globally have been given approval by WHO for EUL, these are Pfizer's Comirnaty, Astrazeneca's AZD1222, Janssen's Ad26.COV2.S, Moderna's mRNA-1273 and Sinopharm's SARS-CoV-2 Vaccine. Russia's Sputnik, China's Sinovac and Cuba have also applied for emergency approval.

Bharat Biotech applies for WHO nod for Covaxin; pre-submission meeting soon

Israel reopened its borders to foreign tourists on Sunday after a fall in <a href="https://www.wionews.com/topics/coronavirus">COVID-19</a> infections but said it would take time for visitors to start arriving and to revive the tourism industry.

Under an easing of coronavirus restrictions, the government went ahead with a plan to start letting in small groups of tourists from countries using vaccines it has approved.

Foreign airlines are also resuming flights they suspended when Palestinian militants began rocket attacks on Israel this month. A ceasefire has now halted the fighting, helping the government meet Sunday's target date for starting the plan.

Also Read |&nbsp;<a href="https://www.wionews.com/world/israeli-strike-puts-sole-gaza-covid-lab-out-of-action-ministry-385816">Israeli strike puts sole Gaza Covid lab out of action: Ministry</a>

But registration for the Tourism Ministry's plan opened only last week, so the number of visitors will initially be limited.

"It is unlikely that the first groups will arrive before the beginning of June," a Tourism Ministry spokeswoman said.

Tourism in 2019 hit a record high of 4.55 million visitors, contributing 23 billion shekels ($7.1 billion) to Israel's economy, mainly via small and mid-sized businesses.

Also Read |&nbsp;<a href="https://www.wionews.com/world/fauci-expects-covid-19-vaccines-for-kids-in-late-2021-sees-need-for-booster-shot-386496">Fauci expects COVID-19 vaccines for kids in late 2021, sees need for booster shot</a>

Under a pilot programme due to continue until June 15, Israel gave the green light to visits by 20 groups of between 5 and 30 tourists from countries including the United States, Britain and Germany.

Another 20 groups were chosen to be on standby if any of the first 20 tour operators did not meet Israel's conditions.

Tourism Minister Orit Farkash-Hacohen said the ministry was working to allow more tourists to enter to "rehabilitate the tourism industry and bring hundreds of thousands of people back into the workforce".

Israeli authorities believe that initially limiting tourism to small groups is the best way to monitor and contain the spread of COVID-19, especially new variants. The plan is to boost the number of groups in June and allow individual tourists to start visiting in July.

Visitors will need to show negative PCR tests before flying and to undergo further tests on arrival.

Israel has fully vaccinated about 55 per cent of its population and COVID-19 cases have dropped sharply.

El Al Israel Airlines Chairman David Brodet said separately on Sunday that he would step down. The government approved a $210 million bailout package for El Al this month that was conditional on steep spending cuts and the airline's owners injecting more cash.

Israel reopened its borders to foreign tourists on Sunday after a fall in COVID-19 infections but said it would take time for visitors to start arriving and to revive the tourism industry.

Israel reopened its borders to foreign tourists on Sunday after a fall in COVID-19 infections but said it would take time for visitors to start arriving and to revive the tourism industry. Under an easing of coronavirus restrictions, the government went ahead with a plan to start letting in small groups of tourists from countries using vaccines it has approved. Foreign airlines are also resuming flights they suspended when Palestinian militants began rocket attacks on Israel this month. A ceasefire has now halted the fighting, helping the government meet Sunday's target date for starting the plan. Also Read | Israeli strike puts sole Gaza Covid lab out of action: Ministry But registration for the Tourism Ministry's plan opened only last week, so the number of visitors will initially be limited. "It is unlikely that the first groups will arrive before the beginning of June," a Tourism Ministry spokeswoman said. Tourism in 2019 hit a record high of 4.55 million visitors, contributing 23 billion shekels ($7.1 billion) to Israel's economy, mainly via small and mid-sized businesses. Also Read | Fauci expects COVID-19 vaccines for kids in late 2021, sees need for booster shot Under a pilot programme due to continue until June 15, Israel gave the green light to visits by 20 groups of between 5 and 30 tourists from countries including the United States, Britain and Germany. Another 20 groups were chosen to be on standby if any of the first 20 tour operators did not meet Israel's conditions. Tourism Minister Orit Farkash-Hacohen said the ministry was working to allow more tourists to enter to "rehabilitate the tourism industry and bring hundreds of thousands of people back into the workforce". Israeli authorities believe that initially limiting tourism to small groups is the best way to monitor and contain the spread of COVID-19, especially new variants. The plan is to boost the number of groups in June and allow individual tourists to start visiting in July. Visitors will need to show negative PCR tests before flying and to undergo further tests on arrival. Israel has fully vaccinated about 55 per cent of its population and COVID-19 cases have dropped sharply. El Al Israel Airlines Chairman David Brodet said separately on Sunday that he would step down. The government approved a $210 million bailout package for El Al this month that was conditional on steep spending cuts and the airline's owners injecting more cash.

Israel reopens borders to small groups of foreign tourists

The cumulative number of COVID-19 vaccine doses administered in the country is 19,49,51,603 on Saturday, the Health Ministry said.&nbsp;

In a statement, it said 6,82,398 beneficiaries of the age group 18-44 years received their first dose on Saturday, and cumulatively 99,79,676 across 37 states/UTs since the start of Phase-3 of the vaccination drive.&nbsp;

Bihar, Rajasthan and Uttar Pradesh have administered more than 10 lakh beneficiaries of the age group 18-44 years for their first dose of Covid vaccine, it said.&nbsp;

The ministry said the total of 19,49,51,603 include 97,52,422 Healthcare Workers (HCWs), who have taken the first dose and 67,00,147 HCWs, who have taken the second dose.&nbsp;

It also includes 1,49,47,941 Frontline Workers (FLWs) (first dose), 83,22,058 FLWs (second dose), and 99,79,676 for 18-44 years of age group (first dose). 6,06,73,244 for over 45 years old to 60 years old (first dose), 97,84,465 for over 45 years old to 60 years old (second dose), 5,65,49,096 for above 60 years (first dose) and 1,82,42,554 for above 60 years (second dose).&nbsp;

As on Day-127 of the vaccination drive (May 22), a total of 15,52,126 vaccine doses were given. As many as 13,80,232 beneficiaries were vaccinated for first dose and 1,71,894 beneficiaries received their second doses, as per the provisional report till 8 pm.&nbsp;

(With inputs from agencies) &nbsp;

The cumulative number of COVID-19 vaccine doses administered in the country is 19,49,51,603 on Saturday, the Health Ministry said. In a statement, it said 6,82,398 beneficiaries of the age group 18-44 years received their first dose on Saturday, and cumulatively 99,79,676 across 37 states/UTs since the start of Phase-3 of the vaccination drive.

The cumulative number of COVID-19 vaccine doses administered in the country is 19,49,51,603 on Saturday, the Health Ministry said. In a statement, it said 6,82,398 beneficiaries of the age group 18-44 years received their first dose on Saturday, and cumulatively 99,79,676 across 37 states/UTs since the start of Phase-3 of the vaccination drive. Bihar, Rajasthan and Uttar Pradesh have administered more than 10 lakh beneficiaries of the age group 18-44 years for their first dose of Covid vaccine, it said. The ministry said the total of 19,49,51,603 include 97,52,422 Healthcare Workers (HCWs), who have taken the first dose and 67,00,147 HCWs, who have taken the second dose. It also includes 1,49,47,941 Frontline Workers (FLWs) (first dose), 83,22,058 FLWs (second dose), and 99,79,676 for 18-44 years of age group (first dose). 6,06,73,244 for over 45 years old to 60 years old (first dose), 97,84,465 for over 45 years old to 60 years old (second dose), 5,65,49,096 for above 60 years (first dose) and 1,82,42,554 for above 60 years (second dose). As on Day-127 of the vaccination drive (May 22), a total of 15,52,126 vaccine doses were given. As many as 13,80,232 beneficiaries were vaccinated for first dose and 1,71,894 beneficiaries received their second doses, as per the provisional report till 8 pm. (With inputs from agencies)

19,49,51,603 vaccine doses administered till now: Centre 

Two doses of the Oxford/AstraZeneca COVID-19 vaccine may be around 85- 90% effective against the symptomatic disease.

Study: 2 Astrazeneca shots 85-90% effective

Profits from <a href="https://www.wionews.com/topics/coronavirus-vaccine">COVID-19 jabs</a> have helped at least nine people become billionaires, a campaign group said Thursday, calling for an end to pharmaceutical corporations' "monopoly control" on vaccine technology.

"Between them, the nine new billionaires have a combined net wealth of $19.3 billion (15.8 billion euros), enough to fully vaccinate all people in low-income countries 1.3 times," The People's Vaccine Alliance said in a statement.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/first-for-asia-singapore-approves-pfizer-vaccine-for-teens-amid-surge-in-covid-19-cases-386055" hreflang="en">First for Asia: Singapore approves Pfizer vaccine for teens amid surge in COVID-19 cases</a>

The alliance, a network of organisations and activists campaigning for an end to property rights and patents for inoculations, said its figures were based on the Forbes Rich List data.&nbsp;

"These billionaires are the human face of the huge profits many pharmaceutical corporations are making from the monopoly they hold on these vaccines," said Anna Marriott from charity Oxfam, which is part of the alliance.

In addition to the new mega-rich, eight existing billionaires have seen their combined wealth increase by $32.2 billion thanks to the vaccine rollout, the alliance said.

<a href="https://www.wionews.com/videos/gravitas-the-pandemic-has-given-birth-to-new-billionaires-386382">Watch |</a>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-the-pandemic-has-given-birth-to-new-billionaires-386382/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Topping the list of new vaccine billionaires were the CEO of Moderna Stephane Bancel, and his BioNTech counterpart Ugur Sahin.

Three other neobillionaires are co-founders of the Chinese vaccine company CanSino Biologics.

The research comes ahead of the G20 Global Health Summit on Friday, which has been a lightning rod for growing calls to temporarily remove intellectual property protections on COVID-19 vaccines.

Proponents say doing so would boost production in developing countries and address the dramatic inequity in access.

The United States, as well as influential figures like Pope Francis, back the idea of a global waiver on patent protections.&nbsp;

At a Paris summit seeking to boost financing in Africa amid the pandemic on Tuesday, French President Emmanuel Macron called for the removal of "all these constraints in terms of intellectual property which blocks the production of certain types of vaccines".

The European Commission said Wednesday it would be a "constructive" voice in WTO talks on the issue.&nbsp;

"The highly effective vaccines we have are thanks to massive amounts of taxpayers’ money so it can’t be fair that private individuals are cashing in while hundreds of millions face second and third waves completely unprotected," said Heidi Chow, Senior Policy and Campaigns Manager at Global Justice Now, which helped analyse the billionaire data.

"As thousands of people die each day in India, it is utterly repugnant... to put the interests of the billionaire owners of Big Pharma ahead of the desperate needs of millions," she added.

Manufacturers have stressed that patent protection is not the limiting factor in ramping up vaccine production.&nbsp;

They say a wide range of issues — from the set up of manufacturing sites, to the sourcing of raw materials, to the availability of qualified personnel — are holding up the manufacturing process.

Profits from COVID-19 jabs have helped at least nine people become billionaires, a campaign group said Thursday, calling for an end to pharmaceutical corporations' "monopoly control" on vaccine technology.

Profits from COVID-19 jabs have helped at least nine people become billionaires, a campaign group said Thursday, calling for an end to pharmaceutical corporations' "monopoly control" on vaccine technology. "Between them, the nine new billionaires have a combined net wealth of $19.3 billion (15.8 billion euros), enough to fully vaccinate all people in low-income countries 1.3 times," The People's Vaccine Alliance said in a statement. Also read | First for Asia: Singapore approves Pfizer vaccine for teens amid surge in COVID-19 cases The alliance, a network of organisations and activists campaigning for an end to property rights and patents for inoculations, said its figures were based on the Forbes Rich List data. "These billionaires are the human face of the huge profits many pharmaceutical corporations are making from the monopoly they hold on these vaccines," said Anna Marriott from charity Oxfam, which is part of the alliance. In addition to the new mega-rich, eight existing billionaires have seen their combined wealth increase by $32.2 billion thanks to the vaccine rollout, the alliance said. Watch | Topping the list of new vaccine billionaires were the CEO of Moderna Stephane Bancel, and his BioNTech counterpart Ugur Sahin. Three other neobillionaires are co-founders of the Chinese vaccine company CanSino Biologics. The research comes ahead of the G20 Global Health Summit on Friday, which has been a lightning rod for growing calls to temporarily remove intellectual property protections on COVID-19 vaccines. Proponents say doing so would boost production in developing countries and address the dramatic inequity in access. The United States, as well as influential figures like Pope Francis, back the idea of a global waiver on patent protections. At a Paris summit seeking to boost financing in Africa amid the pandemic on Tuesday, French President Emmanuel Macron called for the removal of "all these constraints in terms of intellectual property which blocks the production of certain types of vaccines". The European Commission said Wednesday it would be a "constructive" voice in WTO talks on the issue. "The highly effective vaccines we have are thanks to massive amounts of taxpayers’ money so it can’t be fair that private individuals are cashing in while hundreds of millions face second and third waves completely unprotected," said Heidi Chow, Senior Policy and Campaigns Manager at Global Justice Now, which helped analyse the billionaire data. "As thousands of people die each day in India, it is utterly repugnant... to put the interests of the billionaire owners of Big Pharma ahead of the desperate needs of millions," she added. Manufacturers have stressed that patent protection is not the limiting factor in ramping up vaccine production. They say a wide range of issues — from the set up of manufacturing sites, to the sourcing of raw materials, to the availability of qualified personnel — are holding up the manufacturing process.

COVID-19 vaccines have spawned nine new billionaires: Campaign group

Unvaccinated Republican lawmakers pose a danger to other members of Congress and staff, US House Speaker Nancy Pelosi said Thursday as she attacked the "selfishness" of colleagues who refuse to protect against Covid-19.

The top congressional Democrat's criticism of opponents as a health "dangerment" comes as a debate swells over Capitol Hill mask mandates, which Republicans have demanded be lifted as the Biden administration eases its guidance on face coverings.

Also read |&nbsp;<a href="https://www.wionews.com/world/fauci-expects-covid-19-vaccines-for-kids-in-late-2021-sees-need-for-booster-shot-386496" hreflang="en">Fauci expects COVID-19 vaccines for kids in late 2021, sees need for booster shot</a>

"It is unfortunate that a large number of people in the Congress have refused to be vaccinated... or have been vaccinated and don't want to admit it," Pelosi said, noting that Congress's attending physician intends to keep the mask rule in place until all lawmakers get the jab.

"We have a responsibility to make sure that the House of Representatives chamber is not a petri dish because of the selfishness of some not to be vaccinated," Pelosi said.

Also read |&nbsp;<a href="https://www.wionews.com/world/two-astrazeneca-shots-could-be-85-90-effective-uk-data-suggests-386500" hreflang="en">Two AstraZeneca shots could be 85-90% effective, UK data suggests</a>

The biting remarks come days after CNN released a survey of lawmakers that showed a 100 per cent vaccination rate among Democrats in the Senate and House of Representatives, but dramatically lower numbers for Republicans.

Of the House Republicans, just 95 of the conference's 212 members — or 44.8 per cent — told the network they are vaccinated.&nbsp;

An exasperated Pelosi told reporters that committee meetings and other gatherings in Congress will not be able to return to maskless normality until all lawmakers are vaccinated.

"What is this, the honor system... as to whether somebody's been vaccinated?" she said. "Do you want them breathing in your face on the strength of their honor?"

Pelosi has clashed over masks with the chamber's top Republican Kevin McCarthy, who introduced a resolution that would allow lawmakers to be maskless on the House floor.

House Democrats killed the measure.

Some lawmakers have grown openly defiant. Republican Brian Mast said Tuesday he was fined $500 for refusing to wear a mask on the House floor.

Pelosi announced such punishments for mask violations in January.

"This is nothing more than political theatre," House Republican Ralph Norman tweeted Thursday. "All over the Capitol complex, staff and members are maskless. It is time for @SpeakerPelosi to drop the charade."

A recent Morning Consult poll found that unvaccinated Americans are about twice as likely as vaccinated people to say they are comfortable not wearing masks while doing activities like attending a work conference.

Unvaccinated Republican lawmakers pose a danger to other members of Congress and staff, US House Speaker Nancy Pelosi said Thursday as she attacked the "selfishness" of colleagues who refuse to protect against Covid-19.

Unvaccinated Republican lawmakers pose a danger to other members of Congress and staff, US House Speaker Nancy Pelosi said Thursday as she attacked the "selfishness" of colleagues who refuse to protect against Covid-19. The top congressional Democrat's criticism of opponents as a health "dangerment" comes as a debate swells over Capitol Hill mask mandates, which Republicans have demanded be lifted as the Biden administration eases its guidance on face coverings. Also read | Fauci expects COVID-19 vaccines for kids in late 2021, sees need for booster shot "It is unfortunate that a large number of people in the Congress have refused to be vaccinated... or have been vaccinated and don't want to admit it," Pelosi said, noting that Congress's attending physician intends to keep the mask rule in place until all lawmakers get the jab. "We have a responsibility to make sure that the House of Representatives chamber is not a petri dish because of the selfishness of some not to be vaccinated," Pelosi said. Also read | Two AstraZeneca shots could be 85-90% effective, UK data suggests The biting remarks come days after CNN released a survey of lawmakers that showed a 100 per cent vaccination rate among Democrats in the Senate and House of Representatives, but dramatically lower numbers for Republicans. Of the House Republicans, just 95 of the conference's 212 members — or 44.8 per cent — told the network they are vaccinated. An exasperated Pelosi told reporters that committee meetings and other gatherings in Congress will not be able to return to maskless normality until all lawmakers are vaccinated. "What is this, the honor system... as to whether somebody's been vaccinated?" she said. "Do you want them breathing in your face on the strength of their honor?" Pelosi has clashed over masks with the chamber's top Republican Kevin McCarthy, who introduced a resolution that would allow lawmakers to be maskless on the House floor. House Democrats killed the measure. Some lawmakers have grown openly defiant. Republican Brian Mast said Tuesday he was fined $500 for refusing to wear a mask on the House floor. Pelosi announced such punishments for mask violations in January. "This is nothing more than political theatre," House Republican Ralph Norman tweeted Thursday. "All over the Capitol complex, staff and members are maskless. It is time for @SpeakerPelosi to drop the charade." A recent Morning Consult poll found that unvaccinated Americans are about twice as likely as vaccinated people to say they are comfortable not wearing masks while doing activities like attending a work conference.

Unvaccinated US lawmakers a danger to Congress, Pelosi says

Kids in the United States will likely be able to get <a href="https://www.wionews.com/topics/coronavirus-vaccine">COVID-19 vaccinations</a> by the end of this year or the first quarter of 2022, Dr. Anthony Fauci, the nation’s top infectious disease expert, said at an event on Wednesday.

The United States earlier this month cleared the way for the use of the COVID-19 vaccine from Pfizer Inc (PFE.N) and partner BioNTech SE in adolescents aged 12 and above.

Fauci also noted the need for a COVID-19 booster shot within a year or so after getting the primary shot.

Also read |&nbsp;<a href="https://www.wionews.com/world/covid-19-vaccine-patent-waiver-will-not-be-enough-to-bridge-supply-gap-wto-386296" hreflang="en">COVID-19 vaccine patent waiver will not be enough to bridge supply gap: WTO</a>

"I think we will almost certainly require a booster sometime within a year or so after getting the primary because the durability protection against coronavirus is generally not lifelong similar to measles," he said.

Pfizer Chief Executive Officer Albert Bourla at the event said there is likely a need for booster shots between 8-12 months. In April, Bourla told CNBC people will "likely" need a third booster dose of COVID-19 vaccines within 12 months.

Also read |&nbsp;<a href="https://www.wionews.com/world/all-covid-19-virus-variants-respond-to-approved-vaccines-who-386258" hreflang="en">All COVID-19 virus variants respond to approved vaccines: WHO</a>

Scientists, however, are questioning the need for COVID-19 booster shots due to a lack of data to make an informed decision.

There has been significant headway in ensuring vaccine equity, Fauci added, highlighting that the shots should be available in geographic locations easily accessible to minorities as a lesson for the next pandemic.

Kids in the United States will likely be able to get COVID-19 vaccinations by the end of this year or the first quarter of 2022, Dr. Anthony Fauci, the nation’s top infectious disease expert, said at an event on Wednesday.

Kids in the United States will likely be able to get COVID-19 vaccinations by the end of this year or the first quarter of 2022, Dr. Anthony Fauci, the nation’s top infectious disease expert, said at an event on Wednesday. The United States earlier this month cleared the way for the use of the COVID-19 vaccine from Pfizer Inc (PFE.N) and partner BioNTech SE in adolescents aged 12 and above. Fauci also noted the need for a COVID-19 booster shot within a year or so after getting the primary shot. Also read | COVID-19 vaccine patent waiver will not be enough to bridge supply gap: WTO "I think we will almost certainly require a booster sometime within a year or so after getting the primary because the durability protection against coronavirus is generally not lifelong similar to measles," he said. Pfizer Chief Executive Officer Albert Bourla at the event said there is likely a need for booster shots between 8-12 months. In April, Bourla told CNBC people will "likely" need a third booster dose of COVID-19 vaccines within 12 months. Also read | All COVID-19 virus variants respond to approved vaccines: WHO Scientists, however, are questioning the need for COVID-19 booster shots due to a lack of data to make an informed decision. There has been significant headway in ensuring vaccine equity, Fauci added, highlighting that the shots should be available in geographic locations easily accessible to minorities as a lesson for the next pandemic.

Fauci expects COVID-19 vaccines for kids in late 2021, sees need for booster shot

Highlighting the gap of vaccinations between high-income countries and low and lower-middle countries, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus on Monday said that the world is at risk of 'vaccine apartheid'.

Speaking at the Paris Peace Forum Spring Meeting, Tedros Adhanom Ghebreyesus said: "I think I would go one step further and say not just that the world is at risk of vaccine apartheid; the world is in vaccine apartheid." 
 
<a href="https://www.wionews.com/india-news/how-chinese-suppliers-are-profiteering-off-indias-devastating-covid-surge-again-385707">Also read | How Chinese suppliers are profiteering off India's devastating Covid surge... again</a>

"As you know, high-income countries account for 15 per cent of the world's population but have 45 per cent of the world's vaccines. Low- and lower-middle countries account for almost half of the world's population but have received just 17 per cent of the world's vaccines. So the gap is huge," he further remarked.

The WHO chief further highlighted that at least 63 million doses of vaccines have been shipped to 124 countries and economies, but they represent just 0.5 per cent of the combined population of those nations.

 
He also noted that the basic problem of vaccine inequity was a lack of sharing, which could be resolved by sharing financial resources to fully fund the Access to COVID-19 Tools (ACT) Accelerator, sharing doses with COVAX, and sharing technology to scale up the manufacturing of vaccines.

"Even now, some high-income countries are moving to vaccinate children and adolescents, while health workers, older people, and other at-risk groups around the world remain unvaccinated," said Tedros Adhanom Ghebreyesus.

Earlier, US President Joe Biden on Monday (local time) announced that the United States will share 80 million vaccine doses globally over the next six weeks, five times more than any other country has shared to date which represents 13 per cent of vaccines produced in the country by June end.

Joe Biden during his address said, "Today, we're taking an additional step to help the world. We know America will never be fully safe until the pandemic, that's rising globally, is under control. No ocean is wide enough, no walls high enough to keep us safe."

Highlighting the gap of vaccinations between high-income countries and low and lower-middle countries, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus on Monday said that the world is at risk of 'vaccine apartheid'.

Highlighting the gap of vaccinations between high-income countries and low and lower-middle countries, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus on Monday said that the world is at risk of 'vaccine apartheid'. Speaking at the Paris Peace Forum Spring Meeting, Tedros Adhanom Ghebreyesus said: "I think I would go one step further and say not just that the world is at risk of vaccine apartheid; the world is in vaccine apartheid." Also read | How Chinese suppliers are profiteering off India's devastating Covid surge... again "As you know, high-income countries account for 15 per cent of the world's population but have 45 per cent of the world's vaccines. Low- and lower-middle countries account for almost half of the world's population but have received just 17 per cent of the world's vaccines. So the gap is huge," he further remarked. The WHO chief further highlighted that at least 63 million doses of vaccines have been shipped to 124 countries and economies, but they represent just 0.5 per cent of the combined population of those nations. He also noted that the basic problem of vaccine inequity was a lack of sharing, which could be resolved by sharing financial resources to fully fund the Access to COVID-19 Tools (ACT) Accelerator, sharing doses with COVAX, and sharing technology to scale up the manufacturing of vaccines. "Even now, some high-income countries are moving to vaccinate children and adolescents, while health workers, older people, and other at-risk groups around the world remain unvaccinated," said Tedros Adhanom Ghebreyesus. Earlier, US President Joe Biden on Monday (local time) announced that the United States will share 80 million vaccine doses globally over the next six weeks, five times more than any other country has shared to date which represents 13 per cent of vaccines produced in the country by June end. Joe Biden during his address said, "Today, we're taking an additional step to help the world. We know America will never be fully safe until the pandemic, that's rising globally, is under control. No ocean is wide enough, no walls high enough to keep us safe."

World is at risk of 'vaccine apartheid', says WHO chief Tedros Adhanom Ghebreyesus

A government panel on AEFI (adverse events following immunisation) has found 26 potential cases of bleeding and clotting after administration of the COVID-19 vaccine, Covishield, health ministry said on Monday.

According to the statement by the ministry, over 23,000 adverse events have been reported since the vaccination drive involving Covishield and Covaxin vaccines started in the country and of these 700 cases were reported to be serious. 
 
<a href="https://www.wionews.com/india-news/how-chinese-suppliers-are-profiteering-off-indias-devastating-covid-surge-again-385707">Also read | How Chinese suppliers are profiteering off India's devastating Covid surge... again</a> 
 
Some countries have suspended or restricted the use of the shot over fears of possible side effects, though health experts have said its benefits outweigh the risks.

This is the first time India has reported any serious reaction to the use of the vaccine, branded locally as Covishield. 
 
The panel said it had studied 498 (of 700) "serious and severe events" and found that only 26 had been reported as "potential thromboembolic events", referring to the potentially fatal formation of a blood clot that could break loose and be carried by the bloodstream to block another vessel.

“There were no potential thromboembolic events reported following administration of Covaxin vaccine,” the ministry said. As alerts were raised in some countries on post-vaccination embolic and thrombotic events on March 11 particularly with the AstraZeneca-Oxford vaccine (Covishield), a decision was taken to conduct an urgent in-depth analysis of the adverse events (AE) in India in the light of global concerns, the ministry said. The National AEFI committee noted that as of April 3, 75,435,381 vaccine doses had been administered (Covishield- 68,650,819; Covaxin- 6,784,562).

“Of these, 65,944,106 were first doses and 9,491,275 second dose. Since the COVID-19 vaccination drive was initiated more than 23,000 adverse events were reported through the CO-WIN platform reported from 684 of the 753 districts of the country. “Of these, only 700 cases (@ 9.3 cases /million doses administered) were reported to be serious and severe in nature,” the statement said.

“The AEFI data in India showed that there is a very miniscule but definitive risk of thromboembolic events. The reporting rate of these events in India is around 0.61/million doses, which is much lower than the 4 cases/million reported by UK’s regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses,” the statement stated.

Thromboembolic events keep occurring in the general population as background and scientific literature suggests that this risk is almost 70 per cent less in persons of South and South-East Asian descent in comparison to those of European descent. The ministry is separately issuing advisories to healthcare workers and vaccine beneficiaries to encourage people to be aware of suspected thromboembolic symptoms occurring within 20 days after receiving any COVID-19 vaccine (particularly Covishield) and report preferably to the health facility where the vaccine was administered.

The symptoms listed are breathlessness, pain in chest, pain in limbs/pain on pressing limbs or swelling in limbs (arm or calf), multiple, pinhead size red spots or bruising of skin in an area beyond the injection site, persistent abdominal pain with or without vomiting, seizures in the absence of the previous history of seizures with or without vomiting, severe and persistent headache with or without vomiting (in the absence of the previous history of migraine or chronic headache).

The symptoms also include weakness or paralysis of limbs or any particular side or part of the body (including face), persistent vomiting without any obvious reason, blurred vision or pain in eyes or having double vision, change in mental status or having confusion or depression level of consciousness or any other symptom or health condition which is of concern to the recipient of the family. The ministry said that Covishield continues to have a definite positive benefit-risk profile with tremendous potential to prevent infections and reduce deaths due to COVID-19 across the world and in India.

Over 134 million doses of the Covishield vaccine have been administered as of 27 April in India. The ministry is continuously monitoring the safety of all COVID-19 vaccines and is promoting reporting of suspected adverse events.

(With inputs from agencies)

A government panel on AEFI (adverse events following immunisation) has found 26 potential cases of bleeding and clotting after administration of the COVID-19 vaccine, Covishield, health ministry said on Monday.

A government panel on AEFI (adverse events following immunisation) has found 26 potential cases of bleeding and clotting after administration of the COVID-19 vaccine, Covishield, health ministry said on Monday. According to the statement by the ministry, over 23,000 adverse events have been reported since the vaccination drive involving Covishield and Covaxin vaccines started in the country and of these 700 cases were reported to be serious. Also read | How Chinese suppliers are profiteering off India's devastating Covid surge... again Some countries have suspended or restricted the use of the shot over fears of possible side effects, though health experts have said its benefits outweigh the risks. This is the first time India has reported any serious reaction to the use of the vaccine, branded locally as Covishield. The panel said it had studied 498 (of 700) "serious and severe events" and found that only 26 had been reported as "potential thromboembolic events", referring to the potentially fatal formation of a blood clot that could break loose and be carried by the bloodstream to block another vessel. “There were no potential thromboembolic events reported following administration of Covaxin vaccine,” the ministry said. As alerts were raised in some countries on post-vaccination embolic and thrombotic events on March 11 particularly with the AstraZeneca-Oxford vaccine (Covishield), a decision was taken to conduct an urgent in-depth analysis of the adverse events (AE) in India in the light of global concerns, the ministry said. The National AEFI committee noted that as of April 3, 75,435,381 vaccine doses had been administered (Covishield- 68,650,819; Covaxin- 6,784,562). “Of these, 65,944,106 were first doses and 9,491,275 second dose. Since the COVID-19 vaccination drive was initiated more than 23,000 adverse events were reported through the CO-WIN platform reported from 684 of the 753 districts of the country. “Of these, only 700 cases (@ 9.3 cases /million doses administered) were reported to be serious and severe in nature,” the statement said. “The AEFI data in India showed that there is a very miniscule but definitive risk of thromboembolic events. The reporting rate of these events in India is around 0.61/million doses, which is much lower than the 4 cases/million reported by UK’s regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses,” the statement stated. Thromboembolic events keep occurring in the general population as background and scientific literature suggests that this risk is almost 70 per cent less in persons of South and South-East Asian descent in comparison to those of European descent. The ministry is separately issuing advisories to healthcare workers and vaccine beneficiaries to encourage people to be aware of suspected thromboembolic symptoms occurring within 20 days after receiving any COVID-19 vaccine (particularly Covishield) and report preferably to the health facility where the vaccine was administered. The symptoms listed are breathlessness, pain in chest, pain in limbs/pain on pressing limbs or swelling in limbs (arm or calf), multiple, pinhead size red spots or bruising of skin in an area beyond the injection site, persistent abdominal pain with or without vomiting, seizures in the absence of the previous history of seizures with or without vomiting, severe and persistent headache with or without vomiting (in the absence of the previous history of migraine or chronic headache). The symptoms also include weakness or paralysis of limbs or any particular side or part of the body (including face), persistent vomiting without any obvious reason, blurred vision or pain in eyes or having double vision, change in mental status or having confusion or depression level of consciousness or any other symptom or health condition which is of concern to the recipient of the family. The ministry said that Covishield continues to have a definite positive benefit-risk profile with tremendous potential to prevent infections and reduce deaths due to COVID-19 across the world and in India. Over 134 million doses of the Covishield vaccine have been administered as of 27 April in India. The ministry is continuously monitoring the safety of all COVID-19 vaccines and is promoting reporting of suspected adverse events. (With inputs from agencies)

India has 26 cases of bleeding, clotting after Covishield vaccine: Government report

The Palestinian enclave of&nbsp;Gaza's only&nbsp;Covid-19 laboratory is no longer able to carry out testing due to an Israeli air strike Monday on the clinic housing it, local authorities said.

Al-Rimal clinic, in the town of the same name in the&nbsp;Gaza&nbsp;Strip, was partly destroyed, while the territory's health ministry and the office of Qatar's Red Crescent were also hit, officials said.&nbsp;

Also read-&nbsp;<a href="Under pressure, Biden works for ceasefire in Israel-Gaza violence ">Under pressure, Biden works for ceasefire in Israel-Gaza violence&nbsp;</a>

Medical personnel at the ministry were wounded, some critically, the Hamas-run enclave's deputy health minister Yousef Abu al-Rish told reporters.

Ministry spokesman Ashraf Qidra said the Israeli strikes "threaten to undermine the efforts of the health ministry in the face of the&nbsp;Covid&nbsp;pandemic".

Also read-&nbsp;<a href="Need details, justification from Israel for strikes on media outlets in Gaza: US">Need details, justification from Israel for strikes on media outlets in Gaza: US</a>

The raids "stopped screening tests... at the central laboratory", he added.

Before the military escalation between Hamas and Israel a week ago, authorities in&nbsp;Gaza&nbsp;tested an average of some 1,600 people per day.

The rate of positive tests was among the highest in the world, at 28 percent, and hospitals have been overwhelmed by patients.

The enclave of two million residents has so far received 122,000 vaccine doses, more than half of which have not been administered, according to the World Health Organization.&nbsp;

WHO says 103,000 people have tested positive for coronavirus in&nbsp;Gaza, of whom over 930 have died.&nbsp;

The Palestinian enclave of Gaza's only Covid-19 laboratory is no longer able to carry out testing due to an Israeli air strike Monday on the clinic housing it, local authorities said.

The Palestinian enclave of Gaza's only Covid-19 laboratory is no longer able to carry out testing due to an Israeli air strike Monday on the clinic housing it, local authorities said. Al-Rimal clinic, in the town of the same name in the Gaza Strip, was partly destroyed, while the territory's health ministry and the office of Qatar's Red Crescent were also hit, officials said. Also read- Under pressure, Biden works for ceasefire in Israel-Gaza violence Medical personnel at the ministry were wounded, some critically, the Hamas-run enclave's deputy health minister Yousef Abu al-Rish told reporters. Ministry spokesman Ashraf Qidra said the Israeli strikes "threaten to undermine the efforts of the health ministry in the face of the Covid pandemic". Also read- Need details, justification from Israel for strikes on media outlets in Gaza: US The raids "stopped screening tests... at the central laboratory", he added. Before the military escalation between Hamas and Israel a week ago, authorities in Gaza tested an average of some 1,600 people per day. The rate of positive tests was among the highest in the world, at 28 percent, and hospitals have been overwhelmed by patients. The enclave of two million residents has so far received 122,000 vaccine doses, more than half of which have not been administered, according to the World Health Organization. WHO says 103,000 people have tested positive for coronavirus in Gaza, of whom over 930 have died.

Israeli strike puts sole Gaza Covid lab out of action: Ministry

The head of UNICEF on Monday asked G7 countries to donate supplies to the COVAX vaccine-sharing scheme as an emergency measure to address a severe shortfall caused by disruption to Indian vaccine exports.&nbsp;

India has curbed exports of the AstraZeneca vaccine made by its Serum Institute, which had been pledged to COVAX, to be used by the country as it battles a massive second wave of infections.&nbsp;

UN agency UNICEF, which is in charge of supplying coronavirus vaccines through COVAX, estimates the supply shortfall at 140 million doses by the end of May and about 190 million by the end of June.&nbsp;

"Sharing immediately available excess doses is a minimum, essential and emergency stop-gap measure, and it is needed right now," said UNICEF Executive Director Henrietta Fore, adding that this could help to prevent vulnerable countries from becoming the next global hotspot.&nbsp;

As G7 leaders prepare to meet in Britain next month, the head of the World Health Organization last week denounced the 'moral catastrophe' of vaccine inequity, urging wealthy countries to donate doses rather than use them for children, who are less vulnerable to severe disease.&nbsp;

Citing new research from scientific information and analytics company Airfinity, UNICEF's Fore said that G7 countries could donate about 153 million doses if they shared only 20% of their available supply over June, July and August.&nbsp;

This could be done while still meeting commitments to vaccinate their own populations, she said, without providing further detail.&nbsp;

COVAX, run jointly by the WHO and the GAVI vaccine alliance, relies heavily on the AstraZeneca shot, which accounts for the bulk of the vaccines earmarked for early rollout as it seeks to provide two billion doses this year. &nbsp;

UNICEF said that other manufacturing limitations outside India had also slowed supply of COVAX doses but those delays are expected to be resolved by the end of June.&nbsp;

(With inputs from agencies) &nbsp;

The head of UNICEF on Monday asked G7 countries to donate supplies to the COVAX vaccine-sharing scheme as an emergency measure to address a severe shortfall caused by disruption to Indian vaccine exports.

The head of UNICEF on Monday asked G7 countries to donate supplies to the COVAX vaccine-sharing scheme as an emergency measure to address a severe shortfall caused by disruption to Indian vaccine exports. India has curbed exports of the AstraZeneca vaccine made by its Serum Institute, which had been pledged to COVAX, to be used by the country as it battles a massive second wave of infections. UN agency UNICEF, which is in charge of supplying coronavirus vaccines through COVAX, estimates the supply shortfall at 140 million doses by the end of May and about 190 million by the end of June. "Sharing immediately available excess doses is a minimum, essential and emergency stop-gap measure, and it is needed right now," said UNICEF Executive Director Henrietta Fore, adding that this could help to prevent vulnerable countries from becoming the next global hotspot. As G7 leaders prepare to meet in Britain next month, the head of the World Health Organization last week denounced the 'moral catastrophe' of vaccine inequity, urging wealthy countries to donate doses rather than use them for children, who are less vulnerable to severe disease. Citing new research from scientific information and analytics company Airfinity, UNICEF's Fore said that G7 countries could donate about 153 million doses if they shared only 20% of their available supply over June, July and August. This could be done while still meeting commitments to vaccinate their own populations, she said, without providing further detail. COVAX, run jointly by the WHO and the GAVI vaccine alliance, relies heavily on the AstraZeneca shot, which accounts for the bulk of the vaccines earmarked for early rollout as it seeks to provide two billion doses this year. UNICEF said that other manufacturing limitations outside India had also slowed supply of COVAX doses but those delays are expected to be resolved by the end of June. (With inputs from agencies)

G7 urged to donate 'emergency' supplies to vaccine-sharing scheme 

While the whole country is grappling with growing COVID-19 positive cases, the Union Territory of Jammu and Kashmir is witnessing a huge increase in the cases as well COVID-19 related deaths. And the government has said that to beat this second deadly wave in the country, vaccination is the only way out.

However, Kashmir valley is facing an immense shortage of vaccines. According to a government release, not a single dose of vaccine has been given to people in the last 5 days. The J&amp;K media bulletin clearly shows that in all the ten districts of Kashmir valley, not a single vaccine dose has been given to any citizen.

Amarjit Kaur and her father have been coming to the vaccination centre every day for the last 5 consecutive days, but every day they are being sent back as the vaccination centre has no vaccines.&nbsp;

"I have been coming here for almost a week and we are not given a dose, my father is above 50 and he has not been given his first dose yet. They have been telling us every day to come after a few days. My father is a daily wage worker and he has to go out to work so we need him to be vaccinated for sure. They are not vaccinating people above 45, my chance stands very bleak,'' said Amarjit Kaur, a resident.&nbsp;

The daughter-father duo is not the only one who had to return disappointed from the vaccination centre. People in all the ten districts of Kashmir valley are facing the same problem. From daily wagers to Government employees, everyone is waiting for vaccines to arrive so that they can get their Jab.

"They are saying there is no vaccine, we asked them to tell us when it will arrive, they are saying for the next one week they have no idea when it will be available. On one side the Government says get vaccinated and on the other, there are no vaccines available,'' said Ruhi Jan, a government employee.&nbsp;

However, the office of Lt Governor has said that ''A timeline has been set of 10 days for 100 per cent vaccination of above 45 age group with the first dose in all the districts of Jammu and Kashmir''. But the situation on the ground is completely different.&nbsp;

While the whole country is grappling with growing COVID-19 positive cases, the Union Territory of Jammu and Kashmir is witnessing a huge increase in the cases as well COVID-19 related deaths.

While the whole country is grappling with growing COVID-19 positive cases, the Union Territory of Jammu and Kashmir is witnessing a huge increase in the cases as well COVID-19 related deaths. And the government has said that to beat this second deadly wave in the country, vaccination is the only way out. However, Kashmir valley is facing an immense shortage of vaccines. According to a government release, not a single dose of vaccine has been given to people in the last 5 days. The J&K media bulletin clearly shows that in all the ten districts of Kashmir valley, not a single vaccine dose has been given to any citizen. Amarjit Kaur and her father have been coming to the vaccination centre every day for the last 5 consecutive days, but every day they are being sent back as the vaccination centre has no vaccines. "I have been coming here for almost a week and we are not given a dose, my father is above 50 and he has not been given his first dose yet. They have been telling us every day to come after a few days. My father is a daily wage worker and he has to go out to work so we need him to be vaccinated for sure. They are not vaccinating people above 45, my chance stands very bleak,'' said Amarjit Kaur, a resident. The daughter-father duo is not the only one who had to return disappointed from the vaccination centre. People in all the ten districts of Kashmir valley are facing the same problem. From daily wagers to Government employees, everyone is waiting for vaccines to arrive so that they can get their Jab. "They are saying there is no vaccine, we asked them to tell us when it will arrive, they are saying for the next one week they have no idea when it will be available. On one side the Government says get vaccinated and on the other, there are no vaccines available,'' said Ruhi Jan, a government employee. However, the office of Lt Governor has said that ''A timeline has been set of 10 days for 100 per cent vaccination of above 45 age group with the first dose in all the districts of Jammu and Kashmir''. But the situation on the ground is completely different.

COVID-19: Due to acute shortage, vaccine drive grinds to a halt in Kashmir valley

As many as 60,000 doses of the second batch of Russia's COVID-19 vaccine Sputnik V on Sunday landed at Rajiv Gandhi International Airport, Dr Reddy's Laboratories said on Sunday.&nbsp;

"Pleased to share that the consignment that arrived today in Hyderabad contains 60,000 doses of the second dose component of the #SputnikV vaccine. Samples from the consignment will be sent for release to the Central Drugs Laboratory," the drug maker tweeted.&nbsp;

Dr Reddy's Laboratories on May 14 soft launched imported COVID-19 vaccine Sputnik V vaccine, which is priced at Rs 948, with five per cent GST per dose (retail price).&nbsp;

"Given the recent launch of the Russian vaccine in the Indian vaccination campaign, this second delivery has become very timely. The efficacy of the #SputnikV is well-known in the world," Nikolay Kudashev Russian Ambassador to India tweeted.&nbsp;

The first consignment of 1.50 lakh doses of Sputnik V vaccine from Russian Direct Investment Fund (RDIF) landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory.&nbsp;

The Indian drug-maker had earlier said these consignments will be used across different channels as a pilot to line up the supply chain for the larger vaccination programme rollout. &nbsp;

As many as 60,000 doses of the second batch of Russia's COVID-19 vaccine Sputnik V on Sunday landed at Rajiv Gandhi International Airport, Dr Reddy's Laboratories said on Sunday.

As many as 60,000 doses of the second batch of Russia's COVID-19 vaccine Sputnik V on Sunday landed at Rajiv Gandhi International Airport, Dr Reddy's Laboratories said on Sunday. "Pleased to share that the consignment that arrived today in Hyderabad contains 60,000 doses of the second dose component of the #SputnikV vaccine. Samples from the consignment will be sent for release to the Central Drugs Laboratory," the drug maker tweeted. Dr Reddy's Laboratories on May 14 soft launched imported COVID-19 vaccine Sputnik V vaccine, which is priced at Rs 948, with five per cent GST per dose (retail price). "Given the recent launch of the Russian vaccine in the Indian vaccination campaign, this second delivery has become very timely. The efficacy of the #SputnikV is well-known in the world," Nikolay Kudashev Russian Ambassador to India tweeted. The first consignment of 1.50 lakh doses of Sputnik V vaccine from Russian Direct Investment Fund (RDIF) landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory. The Indian drug-maker had earlier said these consignments will be used across different channels as a pilot to line up the supply chain for the larger vaccination programme rollout.

Second batch of Russian COVID-19 vaccine reaches Hyderabad 

Around 1,84,41,478 COVID-19 vaccine doses are still available with states and UTs, while 50,95,640 doses are in the pipeline and will be received by them within the next three days, the Union Health Ministry said on Sunday. &nbsp;

The Centre has so far provided more than 20,28,09,250 vaccine doses to states and UTs free of cost, it said. &nbsp;

Of this, the total consumption, calculated based on average up to May 14, including wastages, is 18,43,67,772 doses, according to data available at 7 pm on Saturday. &nbsp;

"More than 1,84,41,478 Covid vaccine doses are still available with the states and UTs to be administered. States with negative balance are showing more consumption (including wastage) than vaccine supplied as they have not reconciled the vaccine they have supplied to Armed Forces," the ministry said. &nbsp;

It said 50,95,640 vaccine doses are in the pipeline and will be received by states and UTs within the next three days.&nbsp;

Vaccination forms an integral component of the comprehensive strategy of Government of India of containment and management of the pandemic (including test, track, treat and Covid appropriate behaviour). &nbsp;

The Centre has been supporting the nationwide vaccination drive by providing Covid vaccines free of cost to states and UTs, in addition to several efforts to ramp up its production and supply, the ministry stated. &nbsp;

Implementation of the Liberalised and Accelerated Phase 3 Strategy of COVID-19 vaccination has started from May 1 as part of which the government has opened up inoculation for all aged above 18. &nbsp;

Under the Strategy, every month 50 per cent of the total Central Drugs Laboratory (CDL) cleared vaccine doses of any manufacturer would be procured by the Centre. It would continue to make these doses available to state governments free of cost as was being done earlier.

Around 1,84,41,478 COVID-19 vaccine doses are still available with states and UTs, while 50,95,640 doses are in the pipeline and will be received by them within the next three days, the Union Health Ministry said on Sunday.

Around 1,84,41,478 COVID-19 vaccine doses are still available with states and UTs, while 50,95,640 doses are in the pipeline and will be received by them within the next three days, the Union Health Ministry said on Sunday. The Centre has so far provided more than 20,28,09,250 vaccine doses to states and UTs free of cost, it said. Of this, the total consumption, calculated based on average up to May 14, including wastages, is 18,43,67,772 doses, according to data available at 7 pm on Saturday. "More than 1,84,41,478 Covid vaccine doses are still available with the states and UTs to be administered. States with negative balance are showing more consumption (including wastage) than vaccine supplied as they have not reconciled the vaccine they have supplied to Armed Forces," the ministry said. It said 50,95,640 vaccine doses are in the pipeline and will be received by states and UTs within the next three days. Vaccination forms an integral component of the comprehensive strategy of Government of India of containment and management of the pandemic (including test, track, treat and Covid appropriate behaviour). The Centre has been supporting the nationwide vaccination drive by providing Covid vaccines free of cost to states and UTs, in addition to several efforts to ramp up its production and supply, the ministry stated. Implementation of the Liberalised and Accelerated Phase 3 Strategy of COVID-19 vaccination has started from May 1 as part of which the government has opened up inoculation for all aged above 18. Under the Strategy, every month 50 per cent of the total Central Drugs Laboratory (CDL) cleared vaccine doses of any manufacturer would be procured by the Centre. It would continue to make these doses available to state governments free of cost as was being done earlier.

States to receive 50,95,640 COVID-19 vaccine doses in next three days: Centre 

Jill Biden says finally going mask-free feels like 'we're moving forward’. A Republican senator says going unmasked 'certainly helps the flow of conversation’. &nbsp;

But the conversation on the House floor on Friday approached sniping as lawmakers objected to being required to keep masking up until all 435 of them get their COVID-19 shots.&nbsp;

Across Washington, the government is adjusting to new federal guidance easing up on when masks should be worn.&nbsp;

"So much for following the science," Rep Greg Murphy, R-NC, a urologist, said after complaining that he'd have to put his mask back on after his House floor speech despite being fully vaccinated. &nbsp;

The Centers for Disease Control and Prevention said Thursday that fully vaccinated people ‘those who are two weeks past their last required dose of a COVID-19 vaccine’ can stop wearing masks outdoors in crowds and in most indoor settings. Partially vaccinated or unvaccinated people should keep wearing masks, the guidance says. &nbsp;

But on Capitol Hill, lawmakers have to keep wearing masks on the House floor, according to a memo from the Office of the Attending Physician, Dr Brian Monahan. &nbsp;

"The present mask requirement and other guidelines remain unchanged until all Members and Floor staff are fully vaccinated," House Speaker Nancy Pelosi said in a memo to her Democratic colleagues. “Returning the Capitol to the welcoming and safe venue that it has been requires us to not only secure it physically but to make it safe from the virus." Recent surveys suggest that about 1 in 4 House lawmakers are not fully vaccinated.&nbsp;

Lawmakers can remove their masks while on the House floor to make speeches, but must mask up after they finish. They are, however, free to resume 'pre-pandemic activities' elsewhere in the House complex of office buildings and public spaces.&nbsp;

In the Senate, Republicans Susan Collins of Maine and Joni Ernst of Iowa were among senators, who didn't hesitate to remove their masks as soon as they heard the news. They were seen entering the Senate chamber on Thursday marveling at being mask-free and calling out, 'Freedom!'&nbsp;

Senate leadership has not commented on the updated mask guidance, which came down as Biden and a group of Republican senators discussed infrastructure in the Oval Office.&nbsp;

Jill Biden says finally going mask-free feels like 'we're moving forward’. A Republican senator says going unmasked 'certainly helps the flow of conversation’. But the conversation on the House floor on Friday approached sniping as lawmakers objected to being required to keep masking up until all 435 of them get their COVID-19 shots.

Jill Biden says finally going mask-free feels like 'we're moving forward’. A Republican senator says going unmasked 'certainly helps the flow of conversation’. But the conversation on the House floor on Friday approached sniping as lawmakers objected to being required to keep masking up until all 435 of them get their COVID-19 shots. Across Washington, the government is adjusting to new federal guidance easing up on when masks should be worn. "So much for following the science," Rep Greg Murphy, R-NC, a urologist, said after complaining that he'd have to put his mask back on after his House floor speech despite being fully vaccinated. The Centers for Disease Control and Prevention said Thursday that fully vaccinated people ‘those who are two weeks past their last required dose of a COVID-19 vaccine’ can stop wearing masks outdoors in crowds and in most indoor settings. Partially vaccinated or unvaccinated people should keep wearing masks, the guidance says. But on Capitol Hill, lawmakers have to keep wearing masks on the House floor, according to a memo from the Office of the Attending Physician, Dr Brian Monahan. "The present mask requirement and other guidelines remain unchanged until all Members and Floor staff are fully vaccinated," House Speaker Nancy Pelosi said in a memo to her Democratic colleagues. “Returning the Capitol to the welcoming and safe venue that it has been requires us to not only secure it physically but to make it safe from the virus." Recent surveys suggest that about 1 in 4 House lawmakers are not fully vaccinated. Lawmakers can remove their masks while on the House floor to make speeches, but must mask up after they finish. They are, however, free to resume 'pre-pandemic activities' elsewhere in the House complex of office buildings and public spaces. In the Senate, Republicans Susan Collins of Maine and Joni Ernst of Iowa were among senators, who didn't hesitate to remove their masks as soon as they heard the news. They were seen entering the Senate chamber on Thursday marveling at being mask-free and calling out, 'Freedom!' Senate leadership has not commented on the updated mask guidance, which came down as Biden and a group of Republican senators discussed infrastructure in the Oval Office.

Let's face it: Washington adjusts to new mask guidance 

US trade Representative Katherine Tai on Friday virtually met World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus to discuss increasing vaccine production and the Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver on COVID-19 vaccines for the pandemic.&nbsp;

According to a readout from her office, Tai explained the Biden-Harris administration’s support for the waiver of intellectual property protections for COVID-19 vaccines and explained that this fits the United States' comprehensive effort to expand vaccine manufacturing and distribution around the world.&nbsp;

She also asked Ghebreyesus for his views on the immediate steps to collectively increase access to vaccines. Tai asked how the WHO declares the existence, and the end, of a pandemic, and the steps the global health body is taking to increase pandemic preparedness. She and Ghebreyesus also agreed to stay in regular communication in the days ahead. &nbsp;

Earlier, the US Trade Representative also met Union Commerce and Industry Minister Piyush Goyal to discuss on the same issues. As per the readout from her office, Tai conveyed her deep sympathy for the people of India as they battle a wave of COVID-19 cases and reaffirmed the commitment of the United States to help India during its time of need.&nbsp;

She also explained her support for the TRIPS waiver and text-based negotiations at the World Trade Organization (WTO), which are part of the Biden-Harris Administration's comprehensive effort to expand vaccine manufacturing and distribution around the world.&nbsp;

Tai recognised the WTO Members, who have expressed support for future negotiations and welcomed an update from Goyal about India's efforts to revise and resubmit their waiver proposal. She and the Union Minister agreed to stay in regular communication in the days ahead.&nbsp;

The TRIPS waiver aims to increase global vaccine production in order to take on the challenge of vaccinating the poorest of the poor and save lives. In October last year, India and South Africa, along with 57 members of WTO proposed a waiver from certain provisions of the TRIPS agreement for prevention, containment, and treatment of COVID-19.&nbsp;

The WTO agreement on TRIPS is a comprehensive multilateral agreement on intellectual property. US President Joe Biden's administration had on May 6 announced its support for a global waiver on patent protections for COVID-19 vaccines and said it will negotiate the terms at the WTO. &nbsp;

(With inputs from agencies)

US trade Representative Katherine Tai on Friday virtually met World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus to discuss increasing vaccine production and the Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver on COVID-19 vaccines for the pandemic.

US trade Representative Katherine Tai on Friday virtually met World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus to discuss increasing vaccine production and the Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver on COVID-19 vaccines for the pandemic. According to a readout from her office, Tai explained the Biden-Harris administration’s support for the waiver of intellectual property protections for COVID-19 vaccines and explained that this fits the United States' comprehensive effort to expand vaccine manufacturing and distribution around the world. She also asked Ghebreyesus for his views on the immediate steps to collectively increase access to vaccines. Tai asked how the WHO declares the existence, and the end, of a pandemic, and the steps the global health body is taking to increase pandemic preparedness. She and Ghebreyesus also agreed to stay in regular communication in the days ahead. Earlier, the US Trade Representative also met Union Commerce and Industry Minister Piyush Goyal to discuss on the same issues. As per the readout from her office, Tai conveyed her deep sympathy for the people of India as they battle a wave of COVID-19 cases and reaffirmed the commitment of the United States to help India during its time of need. She also explained her support for the TRIPS waiver and text-based negotiations at the World Trade Organization (WTO), which are part of the Biden-Harris Administration's comprehensive effort to expand vaccine manufacturing and distribution around the world. Tai recognised the WTO Members, who have expressed support for future negotiations and welcomed an update from Goyal about India's efforts to revise and resubmit their waiver proposal. She and the Union Minister agreed to stay in regular communication in the days ahead. The TRIPS waiver aims to increase global vaccine production in order to take on the challenge of vaccinating the poorest of the poor and save lives. In October last year, India and South Africa, along with 57 members of WTO proposed a waiver from certain provisions of the TRIPS agreement for prevention, containment, and treatment of COVID-19. The WTO agreement on TRIPS is a comprehensive multilateral agreement on intellectual property. US President Joe Biden's administration had on May 6 announced its support for a global waiver on patent protections for COVID-19 vaccines and said it will negotiate the terms at the WTO. (With inputs from agencies)

US Trade Representative Tai meets WHO chief, discusses vaccine production, TRIPS waiver 

The first dose of the Russian COVID-19 vaccine Sputnik V, which has an efficiency of 91.6 per cent, was administered today in India.

The first consignment of imported doses of the Sputnik V vaccine landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021. 
 
<a href="https://www.wionews.com/science/risk-for-erectile-dysfunction-six-fold-higher-in-men-with-covid-19-384317">Also read: Risk for erectile dysfunction six-fold higher in men with COVID-19</a>

Further consignments of imported doses are expected over the coming months, Dr Reddy's Laboratories said in a statement. Subsequently, the supply of the Sputnik V vaccine will start from Indian manufacturing partners.&nbsp; 
 
<a href="https://www.wionews.com/photos/countries-ripped-apart-by-the-covid-19-pandemic-289245#united-states-289230">Pictures: Countries ripped apart by the COVID-19 pandemic</a> 
 
The imported doses of the vaccine are presently priced at an MRP of ₹ 948 + 5% GST per dose, with the possibility of a lower price point when local supply begins.

The company is working closely with its six manufacturing partners in India to fulfil regulatory requirements to ensure smooth and timely supply.

Dr Reddy`s will work closely with stakeholders in the Government and private sector in India to ensure the widest possible reach of the Sputnik V vaccine as part of the national inoculation effort. This is a reaffirmation of the Company`s commitment to exploring every avenue in the fight against the Covid-19 pandemic in India.

G.V. Prasad, Co-Chairman and Managing Director, said: "With the rising cases in India, vaccination is the most effective tool in our battle against Covid-19. Contributing to the vaccination drive in India is our biggest priority right now to help Indians be healthy and safe."&nbsp;

(With inputs from agencies)

The first dose of the Russian COVID-19 vaccine Sputnik V, which has an efficiency of 91.6 per cent, was administered today in India. The first consignment of imported doses of the Sputnik V vaccine landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021.

The first dose of the Russian COVID-19 vaccine Sputnik V, which has an efficiency of 91.6 per cent, was administered today in India. The first consignment of imported doses of the Sputnik V vaccine landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021. Also read: Risk for erectile dysfunction six-fold higher in men with COVID-19 Further consignments of imported doses are expected over the coming months, Dr Reddy's Laboratories said in a statement. Subsequently, the supply of the Sputnik V vaccine will start from Indian manufacturing partners. Pictures: Countries ripped apart by the COVID-19 pandemic The imported doses of the vaccine are presently priced at an MRP of ₹ 948 + 5% GST per dose, with the possibility of a lower price point when local supply begins. The company is working closely with its six manufacturing partners in India to fulfil regulatory requirements to ensure smooth and timely supply. Dr Reddy`s will work closely with stakeholders in the Government and private sector in India to ensure the widest possible reach of the Sputnik V vaccine as part of the national inoculation effort. This is a reaffirmation of the Company`s commitment to exploring every avenue in the fight against the Covid-19 pandemic in India. G.V. Prasad, Co-Chairman and Managing Director, said: "With the rising cases in India, vaccination is the most effective tool in our battle against Covid-19. Contributing to the vaccination drive in India is our biggest priority right now to help Indians be healthy and safe." (With inputs from agencies)

Sputnik V in India: Vaccine to cost ₹ 995 per shot, made in India may be cheaper

A modelling study has advised delaying the second dose of <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a> to save more lives, similar to the UK’s plan.

Initially, the scientists had developed the vaccines (Moderna, Pfizer-BioNTech, Oxford-AstraZeneca) in such a way that the second shot was advised to be administered within three to four weeks of the first dose.

Also read |&nbsp;<a href="https://www.wionews.com/world/why-offering-a-fat-bonus-to-its-ceo-sets-the-wrong-tone-for-astrazeneca-384620" hreflang="en">Why offering a fat bonus to its CEO sets the wrong tone for AstraZeneca</a>

However, the UK decided to opt for a 12-week gap between the two doses to make sure more people are administered with at least the first shot quickly. Studying the same model, researchers have reported that the immunological evidence proves more protection from the first dose.

The UK’s model has also shown that there have been comparatively fewer infections of covid in people who were administered with the first dose of AstraZeneca and Pfizer coronavirus vaccines. Similarly, Pfizer and Moderna provide nearly 80 per cent protection after the first dose.

Also read |&nbsp;<a href="https://www.wionews.com/world/covid-19-canadas-largest-province-halts-astrazeneca-first-doses-over-blood-clot-384495" hreflang="en">COVID-19: Canada's largest province halts AstraZeneca first doses&nbsp;over blood clot</a>

This study was conducted by scientists at the Mayo Clinic in Rochester who examined&nbsp;models of the UK and other countries that have delayed the second shot due to a shortage of vaccines.

As per their research, delaying the second dose and getting more people vaccinated with the first shot is more advisable as it could save more lives.

This is specifically important for people under the age of 65. The vaccine efficacy is nearly 80 per cent and less than 0.3 per cent of the population is vaccinated with the first dose in a day.

“A delayed second dose vaccination strategy, at least for people aged under 65, could result in reduced cumulative mortality under certain conditions,” the report read.

A modelling study has advised delaying the second dose of coronavirus vaccine to save more lives, similar to the UK’s plan. Initially, the scientists had developed the vaccines (Moderna, Pfizer-BioNTech, Oxford-AstraZeneca) in such a way that the second shot was advised to be administered within three to four weeks of the first dose.

A modelling study has advised delaying the second dose of coronavirus vaccine to save more lives, similar to the UK’s plan. Initially, the scientists had developed the vaccines (Moderna, Pfizer-BioNTech, Oxford-AstraZeneca) in such a way that the second shot was advised to be administered within three to four weeks of the first dose. Also read | Why offering a fat bonus to its CEO sets the wrong tone for AstraZeneca However, the UK decided to opt for a 12-week gap between the two doses to make sure more people are administered with at least the first shot quickly. Studying the same model, researchers have reported that the immunological evidence proves more protection from the first dose. The UK’s model has also shown that there have been comparatively fewer infections of covid in people who were administered with the first dose of AstraZeneca and Pfizer coronavirus vaccines. Similarly, Pfizer and Moderna provide nearly 80 per cent protection after the first dose. Also read | COVID-19: Canada's largest province halts AstraZeneca first doses over blood clot This study was conducted by scientists at the Mayo Clinic in Rochester who examined models of the UK and other countries that have delayed the second shot due to a shortage of vaccines. As per their research, delaying the second dose and getting more people vaccinated with the first shot is more advisable as it could save more lives. This is specifically important for people under the age of 65. The vaccine efficacy is nearly 80 per cent and less than 0.3 per cent of the population is vaccinated with the first dose in a day. “A delayed second dose vaccination strategy, at least for people aged under 65, could result in reduced cumulative mortality under certain conditions,” the report read.

Delaying second doses of Covid vaccines can save more lives: Study

Despite growing concerns from experts around the world, the World Health Organization (WHO) representative to India has assured that the existing <a href="https://www.wionews.com/topics/coronavirus-vaccine">vaccines</a> and diagnostics are effective against the B.1.617 variant of <a href="https://www.wionews.com/topics/coronavirus">coronavirus</a>.

Dr Roderico H Ofrin has issued the statement on the basis of what the WHO knows till now based on the discussions taking place with experts from all over the world, claims Indian news agency ANI.

<a href="https://www.wionews.com/videos/india-records-329942-new-covid-19-cases-3876-deaths-in-last-24-hours-384416">Watch |</a>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/india-records-329942-new-covid-19-cases-3876-deaths-in-last-24-hours-384416/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"There has been an increasing rate of detection of this variant along with an increase and a surge of Covid-19 cases in parts of India. However, the relative contribution of this variant in the rapid increase of cases in the country remains unclear," Ofrin was quoted.

His statement has come at the same time when the WHO announced that the B.1.617&nbsp;variant of coronavirus, which was first identified in India in October, has been detected in more than 4,500 samples from "44 countries in all six WHO regions" through an open-access database.

A day before the variant, which was first found in India in October, has been labelled as a "<a href="https://www.wionews.com/world/who-lists-covid-strain-first-detected-in-india-as-variant-of-concern-384201">variant of concern</a>"&nbsp;and has been added to the list of the deadly variants along with the ones found in Brazil and the UK.&nbsp;

Despite growing concerns from experts around the world, the World Health Organization (WHO) representative to India has assured that the existing vaccines and diagnostics are effective against the B.

Despite growing concerns from experts around the world, the World Health Organization (WHO) representative to India has assured that the existing vaccines and diagnostics are effective against the B.1.617 variant of coronavirus. Dr Roderico H Ofrin has issued the statement on the basis of what the WHO knows till now based on the discussions taking place with experts from all over the world, claims Indian news agency ANI. Watch | "There has been an increasing rate of detection of this variant along with an increase and a surge of Covid-19 cases in parts of India. However, the relative contribution of this variant in the rapid increase of cases in the country remains unclear," Ofrin was quoted. His statement has come at the same time when the WHO announced that the B.1.617 variant of coronavirus, which was first identified in India in October, has been detected in more than 4,500 samples from "44 countries in all six WHO regions" through an open-access database. A day before the variant, which was first found in India in October, has been labelled as a "variant of concern" and has been added to the list of the deadly variants along with the ones found in Brazil and the UK.

Existing vaccines effective against variant from India: WHO official

The tiny Pacific nation of Nauru has congratulated itself for a "world record" COVID-19 <a href="https://www.wionews.com/topics/coronavirus-vaccine">vaccination</a> drive which resulted in all its adult population receiving their first jab.

The remote island nation, one of the few places in the world to remain virus-free, said the four-week vaccination campaign had exceeded expectations.

Also read |&nbsp;<a href="https://www.wionews.com/world/world-will-soon-see-challenges-more-severe-than-covid-19-david-attenborough-384312" hreflang="en">World will soon see challenges more severe than COVID-19: David Attenborough</a>

It said 7,392 people received the first dose, or 108 percent of the estimated adult population, with foreigners included in the figure.

"The National Coronavirus Taskforce is extremely pleased with this world record result and thanks everyone on Nauru for playing their part to keep Nauru Covid free and safe," the government said in a statement.

Also read |&nbsp;<a href="https://www.wionews.com/world/one-astrazeneca-covid-vaccine-dose-cuts-death-risk-by-80-2-pfizer-doses-by-97-uk-agency-384286" hreflang="en">One AstraZeneca Covid vaccine dose cuts death risk by 80%, 2 Pfizer doses by 97%: UK agency</a>

Taskforce chairman Kieren Keke said Nauru was fortunate to have enough vaccine doses to cover its adult population but there was no room for complacency, with testing ongoing to ensure the island remained virus-free.

"With every arriving traveller, the risk of the coronavirus entering Nauru remains and recent events in PNG, Fiji and India have shown how quickly the situation can change," he said.

Nauru received AstraZeneca vaccine doses as part of the global Covax programme aimed at boosting immunisation in poorer nations.

The tiny Pacific nation of Nauru has congratulated itself for a "world record" COVID-19 vaccination drive which resulted in all its adult population receiving their first jab.

The tiny Pacific nation of Nauru has congratulated itself for a "world record" COVID-19 vaccination drive which resulted in all its adult population receiving their first jab. The remote island nation, one of the few places in the world to remain virus-free, said the four-week vaccination campaign had exceeded expectations. Also read | World will soon see challenges more severe than COVID-19: David Attenborough It said 7,392 people received the first dose, or 108 percent of the estimated adult population, with foreigners included in the figure. "The National Coronavirus Taskforce is extremely pleased with this world record result and thanks everyone on Nauru for playing their part to keep Nauru Covid free and safe," the government said in a statement. Also read | One AstraZeneca Covid vaccine dose cuts death risk by 80%, 2 Pfizer doses by 97%: UK agency Taskforce chairman Kieren Keke said Nauru was fortunate to have enough vaccine doses to cover its adult population but there was no room for complacency, with testing ongoing to ensure the island remained virus-free. "With every arriving traveller, the risk of the coronavirus entering Nauru remains and recent events in PNG, Fiji and India have shown how quickly the situation can change," he said. Nauru received AstraZeneca vaccine doses as part of the global Covax programme aimed at boosting immunisation in poorer nations.

Nauru says it vaccinated all adults against Covid in 'world record' effort

A group of health workers in India’s northeastern state of Assam is being questioned about running a <a href="https://www.wionews.com/topics/coronavirus-vaccine">vaccine</a> centre that is allegedly unauthorised.

The vaccination centre was set up at Silchar civil hospital in Assam without completing and following the required process and the health workers had been charging nearly INR 2,000 for each dose.

Also read |&nbsp;<a href="https://www.wionews.com/world/us-mulls-joint-production-of-johnson-johnson-covid-vaccine-with-india-384452" hreflang="en">US mulls joint production of Johnson &amp; Johnson Covid jabs with India</a>

In addition to unauthorised establishment and charging more than the set price, the group has also been accused of not recording details of at least 80 people who had been administered the first shot of Covidshield vaccine.

Nearly 10 vaccine vials were issued in the name of Urban Health Center but were actually used to vaccinate people out of turn at the parallel vaccination centre, authorities from the Assam health department said.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/no-link-between-5g-and-covid-19-as-its-testing-not-yet-started-says-indian-government-384455" hreflang="en">No link between 5G and COVID-19 as its testing not yet started, says Indian government</a>

This centre was being supervised by health worker Swarnajit Paul and senior nurse Sarbani Roy. When the authorities reached the centre, they found more than 100 used empty syringes and a few empty vials of the Covishield vaccine.

Suspicions were raised when a crowd was spotted in a room in the hospital. Upon investigation, Roy and Paul admitted to the crime of administering vaccines to unregistered locals, but they also claimed to be following an order from senior officials.

Also read |&nbsp;<a href="https://www.wionews.com/world/existing-vaccines-effective-against-variant-from-india-who-official-384447" hreflang="en">Existing vaccines effective against variant from India: WHO official</a>

"We vaccinated around 50 people on Monday and 30 people today. I received vaccine vials from a health worker but I don’t know his name. I am a single mother and I have to feed my family with this job. I don’t know if this is legal or not," Surbani Roy said.

Swaranjit Paul, however, claimed the vials used were the ones that were to go to waste as per the guidelines of the waste management scheme. "At least 10% of vaccines get wasted during the process of vaccination, we are allowed to vaccinate people from the half-used vials of vaccine. We started this process on Saturday under waste management but later some new vials were used," he said.

Authorities have assured locals that action against those involved will be taken within 24 hours.

A group of health workers in India’s northeastern state of Assam is being questioned about running a vaccine centre that is allegedly unauthorised. The vaccination centre was set up at Silchar civil hospital in Assam without completing and following the required process and the health workers had been charging nearly INR 2,000 for each dose.

A group of health workers in India’s northeastern state of Assam is being questioned about running a vaccine centre that is allegedly unauthorised. The vaccination centre was set up at Silchar civil hospital in Assam without completing and following the required process and the health workers had been charging nearly INR 2,000 for each dose. Also read | US mulls joint production of Johnson & Johnson Covid jabs with India In addition to unauthorised establishment and charging more than the set price, the group has also been accused of not recording details of at least 80 people who had been administered the first shot of Covidshield vaccine. Nearly 10 vaccine vials were issued in the name of Urban Health Center but were actually used to vaccinate people out of turn at the parallel vaccination centre, authorities from the Assam health department said. Also read | No link between 5G and COVID-19 as its testing not yet started, says Indian government This centre was being supervised by health worker Swarnajit Paul and senior nurse Sarbani Roy. When the authorities reached the centre, they found more than 100 used empty syringes and a few empty vials of the Covishield vaccine. Suspicions were raised when a crowd was spotted in a room in the hospital. Upon investigation, Roy and Paul admitted to the crime of administering vaccines to unregistered locals, but they also claimed to be following an order from senior officials. Also read | Existing vaccines effective against variant from India: WHO official "We vaccinated around 50 people on Monday and 30 people today. I received vaccine vials from a health worker but I don’t know his name. I am a single mother and I have to feed my family with this job. I don’t know if this is legal or not," Surbani Roy said. Swaranjit Paul, however, claimed the vials used were the ones that were to go to waste as per the guidelines of the waste management scheme. "At least 10% of vaccines get wasted during the process of vaccination, we are allowed to vaccinate people from the half-used vials of vaccine. We started this process on Saturday under waste management but later some new vials were used," he said. Authorities have assured locals that action against those involved will be taken within 24 hours.

India: Health workers administering Covishield at unauthorised vaccine centre busted

Canada's largest province said on Tuesday it will stop giving out first doses of the Oxford-AstraZeneca coronavirus vaccine due to concerns over its link to rare blood clots.&nbsp;

Ontario's chief medical officer for health, Dr David Williams, said the decision was made out of an abundance of caution because of increased instances of the rare blood clotting disorder linked to the shot. &nbsp;

AstraZeneca is restricted in some European countries because of a potential link to extremely rare blood clots.&nbsp;

"Over the last few days, there have been increased reports," Williams said. "We are reviewing the data to consider options for the use of the AstraZeneca vaccine for second doses and more broadly."&nbsp;

In Canada, at least 12 cases have been confirmed out of more than two million doses given, and three women have died.&nbsp;

Canadian Prime Minister Justin Trudeau and Ontario Premier Doug Ford both received AstraZeneca first dose in recent weeks. Williams said people who got the first dose of AstraZeneca 'absolutely did the right thing’.&nbsp;

Dr Andrew Morris, a professor of infectious diseases at the University of Toronto and the medical director of the Antimicrobial Stewardship Programme at Sinai-University Health Network, does not believe Canada should be using AstraZeneca any longer now that Canada has large supplies of other vaccines.&nbsp;

"It's the right thing to do," he said.&nbsp;

Morris said experts don't know yet what to do about people, who got only the first dose. Health officials are awaiting results of a clinical trial in the United Kingdom looking at giving a different vaccine for the second dose. That would allow people, who got AstraZeneca first to be given Pfizer or Moderna for their second dose.&nbsp;

Alberta is also no longer administrating first doses of the AstraZeneca vaccine but only because of a lack of supply. &nbsp;

Pfizer and Moderna are sending more than enough doses to vaccinate every Canadian with two doses eventually.&nbsp;

Trudeau said almost 50% of eligible adults in Canada have received at least one shot of a coronavirus vaccine. Most of that is Pfizer and Moderna. &nbsp;

Trudeau said by the summer, Canada will have enough vaccines so that every eligible resident will have gotten their first dose and by September, it will have enough doses for everyone to be fully vaccinated. &nbsp;

(With inputs from agencies)&nbsp;

Canada's largest province said on Tuesday it will stop giving out first doses of the Oxford-AstraZeneca coronavirus vaccine due to concerns over its link to rare blood clots.

Canada's largest province said on Tuesday it will stop giving out first doses of the Oxford-AstraZeneca coronavirus vaccine due to concerns over its link to rare blood clots. Ontario's chief medical officer for health, Dr David Williams, said the decision was made out of an abundance of caution because of increased instances of the rare blood clotting disorder linked to the shot. AstraZeneca is restricted in some European countries because of a potential link to extremely rare blood clots. "Over the last few days, there have been increased reports," Williams said. "We are reviewing the data to consider options for the use of the AstraZeneca vaccine for second doses and more broadly." In Canada, at least 12 cases have been confirmed out of more than two million doses given, and three women have died. Canadian Prime Minister Justin Trudeau and Ontario Premier Doug Ford both received AstraZeneca first dose in recent weeks. Williams said people who got the first dose of AstraZeneca 'absolutely did the right thing’. Dr Andrew Morris, a professor of infectious diseases at the University of Toronto and the medical director of the Antimicrobial Stewardship Programme at Sinai-University Health Network, does not believe Canada should be using AstraZeneca any longer now that Canada has large supplies of other vaccines. "It's the right thing to do," he said. Morris said experts don't know yet what to do about people, who got only the first dose. Health officials are awaiting results of a clinical trial in the United Kingdom looking at giving a different vaccine for the second dose. That would allow people, who got AstraZeneca first to be given Pfizer or Moderna for their second dose. Alberta is also no longer administrating first doses of the AstraZeneca vaccine but only because of a lack of supply. Pfizer and Moderna are sending more than enough doses to vaccinate every Canadian with two doses eventually. Trudeau said almost 50% of eligible adults in Canada have received at least one shot of a coronavirus vaccine. Most of that is Pfizer and Moderna. Trudeau said by the summer, Canada will have enough vaccines so that every eligible resident will have gotten their first dose and by September, it will have enough doses for everyone to be fully vaccinated. (With inputs from agencies)

COVID-19: Canada's largest province halts AstraZeneca first doses over blood clot

The US is eyeing joint production of the Johnson &amp; Johnson coronavirus <a href="https://www.wionews.com/topics/coronavirus-vaccine">vaccine</a> with India, aiming to ramp up production of the jabs.

US chargé d’affaires Daniel Smith has revealed that the US government is in talks with its Indian counterpart to arrange the raw materials — listed by India — needed to manufacture the vaccines. However, he has also cautioned that this will not be an easy task as the global supply chains are currently disrupted all over the world.

Also read |&nbsp;<a href="https://www.wionews.com/world/existing-vaccines-effective-against-variant-from-india-who-official-384447" hreflang="en">Existing vaccines effective against variant from India: WHO official</a>

"We are now working closely with them to go through this list to decide what is available, what we can provide and how quickly we can provide that. I just want to say this is not an easy task, that is, there are global challenges in the global supply chain right now when it comes to precursors and raw materials necessary for these vaccines,"&nbsp; Smith said.

He also clarified that in addition to eyeing a joint production of the J&amp;J vaccine with India, the US government is also working with Serum Institute of India (SII) and a few other vaccine manufacturers to increase the speed and quantity of vaccines being produced amid a covid crisis in the South Asian country.

Also read |&nbsp;<a href="https://www.wionews.com/world/we-can-do-this-uber-lyft-offer-rides-to-americans-for-covid-vaccination-mcdonalds-chips-in-too-384438" hreflang="en">We can do this: Uber, Lyft offer rides to Americans for Covid vaccination, McDonald's chips in too</a>

"I know [the US International] Development Finance Corporation (DFC) is looking at how we can invest so that we can help produce the Johnson &amp; Johnson vaccine here in India," he said.

The US is also urging several private sector discussions to increase the manufacturing of vaccines.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/covid-19-in-india-348421-fresh-cases-4205-deaths-in-last-24-hours-384432" hreflang="en">COVID-19 in India: 3,48,421 fresh cases, 4205 deaths in last 24 hours</a>

"I think we are watching carefully the production levels at the SII and elsewhere. We’ve been in close touch with the SII to try to determine what raw materials we could provide, and assistance that we can provide to help boost production. But that’s an issue with vaccines across the board, it’s not simply with the AstraZeneca vaccine in that regard," he was quoted by an Indian newspaper, Hindustan Times.

He also addressed the issue of the US holding on to a few doses of the AstraZeneca vaccine. He has claimed the doses will not be passed on till the FDA approves them in the safety check.

"I know that there are a number of doses of the AstraZeneca vaccine that were made in the plant outside of Baltimore, but there were problems with this plant. So far, the FDA hasn’t certified that these vaccines are available for anyone’s use, for export or not. So I can’t say when that will happen or what will be done exactly as we go forward,"&nbsp;he said.

The US is eyeing joint production of the Johnson & Johnson coronavirus vaccine with India, aiming to ramp up production of the jabs. US chargé d’affaires Daniel Smith has revealed that the US government is in talks with its Indian counterpart to arrange the raw materials — listed by India — needed to manufacture the vaccines.

The US is eyeing joint production of the Johnson & Johnson coronavirus vaccine with India, aiming to ramp up production of the jabs. US chargé d’affaires Daniel Smith has revealed that the US government is in talks with its Indian counterpart to arrange the raw materials — listed by India — needed to manufacture the vaccines. However, he has also cautioned that this will not be an easy task as the global supply chains are currently disrupted all over the world. Also read | Existing vaccines effective against variant from India: WHO official "We are now working closely with them to go through this list to decide what is available, what we can provide and how quickly we can provide that. I just want to say this is not an easy task, that is, there are global challenges in the global supply chain right now when it comes to precursors and raw materials necessary for these vaccines," Smith said. He also clarified that in addition to eyeing a joint production of the J&J vaccine with India, the US government is also working with Serum Institute of India (SII) and a few other vaccine manufacturers to increase the speed and quantity of vaccines being produced amid a covid crisis in the South Asian country. Also read | We can do this: Uber, Lyft offer rides to Americans for Covid vaccination, McDonald's chips in too "I know [the US International] Development Finance Corporation (DFC) is looking at how we can invest so that we can help produce the Johnson & Johnson vaccine here in India," he said. The US is also urging several private sector discussions to increase the manufacturing of vaccines. Also read | COVID-19 in India: 3,48,421 fresh cases, 4205 deaths in last 24 hours "I think we are watching carefully the production levels at the SII and elsewhere. We’ve been in close touch with the SII to try to determine what raw materials we could provide, and assistance that we can provide to help boost production. But that’s an issue with vaccines across the board, it’s not simply with the AstraZeneca vaccine in that regard," he was quoted by an Indian newspaper, Hindustan Times. He also addressed the issue of the US holding on to a few doses of the AstraZeneca vaccine. He has claimed the doses will not be passed on till the FDA approves them in the safety check. "I know that there are a number of doses of the AstraZeneca vaccine that were made in the plant outside of Baltimore, but there were problems with this plant. So far, the FDA hasn’t certified that these vaccines are available for anyone’s use, for export or not. So I can’t say when that will happen or what will be done exactly as we go forward," he said.

US mulls joint production of Johnson & Johnson Covid vaccine with India

Hong Kong on Tuesday scrapped a plan to make coronavirus vaccines mandatory for foreign domestic workers after the proposal sparked an outcry and a diplomatic tussle with the Philippines.

Health officials planned to roll out mandatory inoculations for the 370,000 domestic workers in the city, mostly poorly paid women from the Philippines and Indonesia.

Also read |&nbsp;<a href="Chinese scientists discussed weaponising SARS coronaviruses 5 years back: Report">Chinese scientists discussed weaponising SARS coronaviruses 5 years back: Report</a>

Those wanting to apply for work visas -- or renew their current ones -- would need to show they had received two doses.

But on Tuesday city leader Carrie Lam announced a U-turn.&nbsp;

Also read |&nbsp;<a href="China's past on coronavirus comes back to haunt it">China's past on coronavirus comes back to haunt it</a>

" The government has decided not to request mandatory vaccination when helpers renew their contracts,"&nbsp;she said, adding the decision had been made after meetings with officials from the Philippines and Indonesia.

Philippine foreign affairs secretary Teodoro Locsin had previously warned the initial proposal "smacked of discrimination".

Also read |&nbsp;<a href="Hong Kong widens COVID-19 vaccine scheme to above 16">Hong Kong widens COVID-19 vaccine scheme to above 16</a>

Hong Kong health officials announced the mandatory vaccination plan after two domestic workers were found to be infected with one of the more virulent strains of the coronavirus.

They said domestic workers were 'high risk'&nbsp;because they often work with the elderly and meet in parks on Sundays -- usually their one day off a week.

Labour groups representing domestic workers said they felt they were being singled out, noting that the families they worked for -- as well as locals working in environments such as care homes -- were not required to get vaccinated.

They also pointed out that wealthier foreign migrants such as the city's white-collar financial workers were not forced to get vaccines when outbreaks of the coronavirus were traced to their well-heeled districts.

Thanks to strict quarantine measures and economically painful social distancing rules, Hong Kong has kept infections to just under 12,000 cases and 210 deaths.

It has secured ample vaccine doses but the public take-up has been very low.

So far just 16 percent of the city's 7.5 million people have received one or more doses, a long way from the 60-70 percent considered necessary for herd immunity.

Regular polling shows Hong Kongers have some of the lowest support ratings for inoculation in the world.

Some of Hong Kong's BioNTech/Pfizer vaccines will pass their shelf-life in September and officials fret they may be in the unenviable position of throwing away good doses.

The vaccination drive has been hampered by the government's public trust deficit.

After huge democracy protests exploded in 2019, Hong Kong's unpopular unelected leaders -- with the backing of Beijing -- have overseen a sweeping crackdown in dissent in the city.

Hong Kong on Tuesday scrapped a plan to make coronavirus vaccines mandatory for foreign domestic workers after the proposal sparked an outcry and a diplomatic tussle with the Philippines.

Hong Kong on Tuesday scrapped a plan to make coronavirus vaccines mandatory for foreign domestic workers after the proposal sparked an outcry and a diplomatic tussle with the Philippines. Health officials planned to roll out mandatory inoculations for the 370,000 domestic workers in the city, mostly poorly paid women from the Philippines and Indonesia. Also read | Chinese scientists discussed weaponising SARS coronaviruses 5 years back: Report Those wanting to apply for work visas -- or renew their current ones -- would need to show they had received two doses. But on Tuesday city leader Carrie Lam announced a U-turn. Also read | China's past on coronavirus comes back to haunt it " The government has decided not to request mandatory vaccination when helpers renew their contracts," she said, adding the decision had been made after meetings with officials from the Philippines and Indonesia. Philippine foreign affairs secretary Teodoro Locsin had previously warned the initial proposal "smacked of discrimination". Also read | Hong Kong widens COVID-19 vaccine scheme to above 16 Hong Kong health officials announced the mandatory vaccination plan after two domestic workers were found to be infected with one of the more virulent strains of the coronavirus. They said domestic workers were 'high risk' because they often work with the elderly and meet in parks on Sundays -- usually their one day off a week. Labour groups representing domestic workers said they felt they were being singled out, noting that the families they worked for -- as well as locals working in environments such as care homes -- were not required to get vaccinated. They also pointed out that wealthier foreign migrants such as the city's white-collar financial workers were not forced to get vaccines when outbreaks of the coronavirus were traced to their well-heeled districts. Thanks to strict quarantine measures and economically painful social distancing rules, Hong Kong has kept infections to just under 12,000 cases and 210 deaths. It has secured ample vaccine doses but the public take-up has been very low. So far just 16 percent of the city's 7.5 million people have received one or more doses, a long way from the 60-70 percent considered necessary for herd immunity. Regular polling shows Hong Kongers have some of the lowest support ratings for inoculation in the world. Some of Hong Kong's BioNTech/Pfizer vaccines will pass their shelf-life in September and officials fret they may be in the unenviable position of throwing away good doses. The vaccination drive has been hampered by the government's public trust deficit. After huge democracy protests exploded in 2019, Hong Kong's unpopular unelected leaders -- with the backing of Beijing -- have overseen a sweeping crackdown in dissent in the city.

Hong Kong scraps mandatory vaccines for foreign domestic workers

Venezuela's main academy of medicine has asked the United States to add the South American nation to its international donor list for millions of doses of COVID-19 vaccines, despite a political freeze between the two countries.

Enrique Lopez-Loyo, president of the politically independent National Academy of Medicine, made the request to U.S. Ambassador to Venezuela James Story at a meeting on May 2, the academy said in a statement on Monday.

Also read |&nbsp;<a href="US approves Pfizer-BioNTech's Covid vaccine for children aged 12-15">US approves Pfizer-BioNTech's Covid vaccine for children aged 12-15</a>

"To control the pandemic in our country, we need to vaccinate around 70% of the adult population, nearly 15 million people, in as little time as possible," the academy said in the statement. "The amount of vaccines that have arrived to Venezuela ... represents less than 10% of what Venezuela needs."

Venezuela has received around 1.4 million vaccines from China and Russia, according to the Health Ministry, and hopes to receive doses for about 5 million people from the World Health Organization's (WHO) COVAX program.

Also read |&nbsp;<a href="'Vaccine tourists' fly in from abroad for injections on US beach ">'Vaccine tourists' fly in from abroad for injections on US beach&nbsp;</a>

The academy is a member of the Venezuelan government's round table developing a response to the coronavirus crisis for its 30 million people.

The academy's plea, however, for U.S. supplies of AstraZeneca PLC vaccines runs contrary to the government's refusal in March to authorize the vaccine because of reports of blood clotting in some recipients.

The academy's request also comes amid U.S. sanctions on Venezuela to protest the re-election of President Nicolas Maduro in 2018 in elections it, and many other nations, viewed as fraudulent. Venezuela blames Washington's sanctions for its economic woes.

Story, appointed at the end of last year, is based in Bogota, Colombia, because of the rupture in relations.

The academy said Story responded to its request, saying the United States valued the independence of the academy and it looked 'forward to working with all like-minded parties in the search for a solution to this crisis.'

Venezuela's information ministry did not immediately respond to a request for comment.

Venezuela has reported a total of around 209,000 COVID-19 cases, including some 2,300 deaths.

Venezuela's main academy of medicine has asked the United States to add the South American nation to its international donor list for millions of doses of COVID-19 vaccines, despite a political freeze between the two countries.

Venezuela's main academy of medicine has asked the United States to add the South American nation to its international donor list for millions of doses of COVID-19 vaccines, despite a political freeze between the two countries. Enrique Lopez-Loyo, president of the politically independent National Academy of Medicine, made the request to U.S. Ambassador to Venezuela James Story at a meeting on May 2, the academy said in a statement on Monday. Also read | US approves Pfizer-BioNTech's Covid vaccine for children aged 12-15 "To control the pandemic in our country, we need to vaccinate around 70% of the adult population, nearly 15 million people, in as little time as possible," the academy said in the statement. "The amount of vaccines that have arrived to Venezuela ... represents less than 10% of what Venezuela needs." Venezuela has received around 1.4 million vaccines from China and Russia, according to the Health Ministry, and hopes to receive doses for about 5 million people from the World Health Organization's (WHO) COVAX program. Also read | 'Vaccine tourists' fly in from abroad for injections on US beach The academy is a member of the Venezuelan government's round table developing a response to the coronavirus crisis for its 30 million people. The academy's plea, however, for U.S. supplies of AstraZeneca PLC vaccines runs contrary to the government's refusal in March to authorize the vaccine because of reports of blood clotting in some recipients. The academy's request also comes amid U.S. sanctions on Venezuela to protest the re-election of President Nicolas Maduro in 2018 in elections it, and many other nations, viewed as fraudulent. Venezuela blames Washington's sanctions for its economic woes. Story, appointed at the end of last year, is based in Bogota, Colombia, because of the rupture in relations. The academy said Story responded to its request, saying the United States valued the independence of the academy and it looked 'forward to working with all like-minded parties in the search for a solution to this crisis.' Venezuela's information ministry did not immediately respond to a request for comment. Venezuela has reported a total of around 209,000 COVID-19 cases, including some 2,300 deaths.

Venezuela's academy of medicine asks US to donate COVID-19 vaccines

Vaccine hesitancy, in other words, delay or refusal to take a vaccine, is more common than thought. It is the biggest threat to global vaccine rollout. Bigger than shortage and side effects.

Vaccine hesitancy is as old as vaccines themselves. There is no single reason for it. In some places, hesitancy is based on religion. Elsewhere, it is politics. But whatever the reason,&nbsp;the end result is never good.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-is-the-who-feeding-vaccine-hesitancy-384187/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Look at some of the examples from history. These are all instances where vaccine hesitancy led to outbreaks.

In 1873 in Stockholm, vaccination rate dropped from 90 per cent&nbsp;to 40 per cent. It was triggered by a religious anti-vax campaign.

A deadly smallpox epidemic spread that same year.

Another example is from UK and Ireland. In year 2000, people started linking the measles vaccine to Autism. The vaccination rates dropped below 80 per cent. There were 300 cases, 100 hospitalisations and three deaths. All of this was preventable.

The bottomline is that vaccine hesitancy is dangerous. Deadly in fact. The World Health Organisation (WHO) ranks it as one of the top 10 global health threats.

A proper messaging right from the top can beat this threat.

One would expect WHO to give facts and robust advice. Instead, there is confusion and conjecture.

On Saturday, WHO's Chief Scientist Soumya Swaminathan was talking about Wuhan virus variant detected in India.

"The one (variant) that was first identified in India,&nbsp;the B 1.617 is likely to be a variant of concern because it has some mutations, which increase transmission, and which also potentially could make them resistant to antibodies that are generated by vaccination or by natural infection," she said.

'Likely' and 'potentially' are the words you don't want health experts to say. Because this is in the realm of possibility.

Words have consequences, especially when coming from the WHO's top scientist. She says the new variants may evade the vaccines. There are a lot of people undecided on whether to get the shot. And those people may be swayed by such remarks. They may think if the WHO says it's pointless, why take it?

This is irresponsible, not to mention dangerous. When top officials make such careless remarks, it becomes our duty to set the record straight.

The vaccines are safe and effective. Variant or not,&nbsp;make sure you get the shot at the earliest.

And can the variant really dodge the vaccine?

Last week India's top medical body ICMR published a study. It concluded that Bharat Biotech's Covaxin was effective against the double mutant.

So was the WHO not aware of this study? Or did they choose to ignore it? Or do they disagree with it?

Messaging and response from WHO has been botched up from the word go. WHO did nothing for more than a month when it got news of the virus in December 2019.

It was on January 30 that Dr Tedros finally declare a public health emergency. It took him another month to utter the word pandemic. A lot of harm was done during this time. Some countries banned travel links with China. They were declared racist by the WHO. Dr Tedros called these bans an unnecessary interference. One year later, those countries stand vindicated.

What about lockdowns? The WHO's envoy David Nabarro said lockdowns should be the last resort. Today this is true because we have vaccines. But last year, this advice made no sense. Lockdowns were humanity's first line of defence. It was a circuit breaker for countries to build up resources.

But nothing compares to the WHO's advice on masks.

The headline saying "Face masks could do more harm than good if used incorrectly" is a classic example of negative advice.

The WHO is trying to ask people to wear their masks correctly, but the statement does the opposite. It scares them.

They instead should have made a campaign video on how to wear masks correctly. This is communication 101. Positive messages stick, negative don't.&nbsp;

These are just a few instances where the WHO stumbled. Unfortunately, it happened all the time last year. From masks to lockdowns to travel bans to now vaccines.

The WHO has been like a loose cannon. Firing off assumptions and conjectures. These things are normally expected from politicians and not from health experts.

But then again, the WHO stopped being a health body in 2020.

Vaccine hesitancy, in other words, delay or refusal to take a vaccine, is more common than thought. It is the biggest threat to global vaccine rollout. Bigger than shortage and side effects.

Vaccine hesitancy, in other words, delay or refusal to take a vaccine, is more common than thought. It is the biggest threat to global vaccine rollout. Bigger than shortage and side effects. Vaccine hesitancy is as old as vaccines themselves. There is no single reason for it. In some places, hesitancy is based on religion. Elsewhere, it is politics. But whatever the reason, the end result is never good. × Look at some of the examples from history. These are all instances where vaccine hesitancy led to outbreaks. In 1873 in Stockholm, vaccination rate dropped from 90 per cent to 40 per cent. It was triggered by a religious anti-vax campaign. A deadly smallpox epidemic spread that same year. Another example is from UK and Ireland. In year 2000, people started linking the measles vaccine to Autism. The vaccination rates dropped below 80 per cent. There were 300 cases, 100 hospitalisations and three deaths. All of this was preventable. The bottomline is that vaccine hesitancy is dangerous. Deadly in fact. The World Health Organisation (WHO) ranks it as one of the top 10 global health threats. A proper messaging right from the top can beat this threat. One would expect WHO to give facts and robust advice. Instead, there is confusion and conjecture. On Saturday, WHO's Chief Scientist Soumya Swaminathan was talking about Wuhan virus variant detected in India. "The one (variant) that was first identified in India, the B 1.617 is likely to be a variant of concern because it has some mutations, which increase transmission, and which also potentially could make them resistant to antibodies that are generated by vaccination or by natural infection," she said. 'Likely' and 'potentially' are the words you don't want health experts to say. Because this is in the realm of possibility. Words have consequences, especially when coming from the WHO's top scientist. She says the new variants may evade the vaccines. There are a lot of people undecided on whether to get the shot. And those people may be swayed by such remarks. They may think if the WHO says it's pointless, why take it? This is irresponsible, not to mention dangerous. When top officials make such careless remarks, it becomes our duty to set the record straight. The vaccines are safe and effective. Variant or not, make sure you get the shot at the earliest. And can the variant really dodge the vaccine? Last week India's top medical body ICMR published a study. It concluded that Bharat Biotech's Covaxin was effective against the double mutant. So was the WHO not aware of this study? Or did they choose to ignore it? Or do they disagree with it? Messaging and response from WHO has been botched up from the word go. WHO did nothing for more than a month when it got news of the virus in December 2019. It was on January 30 that Dr Tedros finally declare a public health emergency. It took him another month to utter the word pandemic. A lot of harm was done during this time. Some countries banned travel links with China. They were declared racist by the WHO. Dr Tedros called these bans an unnecessary interference. One year later, those countries stand vindicated. What about lockdowns? The WHO's envoy David Nabarro said lockdowns should be the last resort. Today this is true because we have vaccines. But last year, this advice made no sense. Lockdowns were humanity's first line of defence. It was a circuit breaker for countries to build up resources. But nothing compares to the WHO's advice on masks. The headline saying "Face masks could do more harm than good if used incorrectly" is a classic example of negative advice. The WHO is trying to ask people to wear their masks correctly, but the statement does the opposite. It scares them. They instead should have made a campaign video on how to wear masks correctly. This is communication 101. Positive messages stick, negative don't. These are just a few instances where the WHO stumbled. Unfortunately, it happened all the time last year. From masks to lockdowns to travel bans to now vaccines. The WHO has been like a loose cannon. Firing off assumptions and conjectures. These things are normally expected from politicians and not from health experts. But then again, the WHO stopped being a health body in 2020.

Clear message from top is needed to battle vaccine hesitancy

The head of German pharmaceutical company BioNTech said on Monday that there is no need to waive patents on coronavirus vaccines because manufacturers will be able to produce enough shots to supply the world over the coming year.&nbsp;

Ugur Sahin, the chief executive of BioNTech, rejected the US-backed proposal to temporarily lift some intellectual property rights for vaccines in order to boost global supply during the ongoing pandemic.&nbsp;

In a call with investors announcing the company’s first-quarter net profit of 1.13 billion euros ($1.37 billion), Sahin said BioNTech and its US partner Pfizer had already delivered vaccines to more than 90 countries and more than doubled its forecast production capacity for the year.&nbsp;

“We have now scaled the manufacturing capacity up to 3 billion doses in 2021, and more than 40% of these doses are expected to go to middle- and low-income countries,” Sahin said.&nbsp;

Waiving patents would not ease supply shortages in the coming months, he said, citing the complexity of producing the mRNA-based shot his company developed last year.&nbsp;

Sahin said his company is working to further expand its manufacturing network with its own sites, such as one now planned in Singapore, and through cooperation with other manufacturers to ensure greater supply while maintaining the quality of the vaccine. But he also noted that rival manufacturers have their own shots either on the market already or in the pipeline.&nbsp;

“We believe, together with the other vaccine developers, in the next 9 to 12 months, that there will be more than enough vaccine produced and there is absolutely no need for waiving patents,” he said.&nbsp;

BioNTech’s estimated revenues surged to over two billion euros for the period from January to March, compared with just 28 million euros in the same period last year, after it launched the first widely used vaccine against COVID-19 together with Pfizer, which holds the market and distribution rights in much of the world.&nbsp;

The Mainz-based company said its revenues included over 1.75 billion euros in gross profits from vaccine sales in Pfizer’s territories, and almost 200 million from sales to customers in its region. Based on current orders for some 1.8 billion doses, it expects full-year revenues of 12.4 billion euros in 2021.&nbsp;

BioNTech shares rose by more than 7% to $196.60 in early trading on Monday on Nasdaq.&nbsp;

The results are a significant turnaround for the company, which made a net loss of 53 million euros in the first quarter of 2020.&nbsp;

Early last year as the pandemic began, BioNTech pivoted from researching treatments for cancer to developing a vaccine against COVID-19. Like its rival Moderna, the company’s vaccine uses mRNA technology to prime the body’s immune system to attack the virus.&nbsp;

(With inputs from agencies)&nbsp;

The head of German pharmaceutical company BioNTech said on Monday that there is no need to waive patents on coronavirus vaccines because manufacturers will be able to produce enough shots to supply the world over the coming year.

The head of German pharmaceutical company BioNTech said on Monday that there is no need to waive patents on coronavirus vaccines because manufacturers will be able to produce enough shots to supply the world over the coming year. Ugur Sahin, the chief executive of BioNTech, rejected the US-backed proposal to temporarily lift some intellectual property rights for vaccines in order to boost global supply during the ongoing pandemic. In a call with investors announcing the company’s first-quarter net profit of 1.13 billion euros ($1.37 billion), Sahin said BioNTech and its US partner Pfizer had already delivered vaccines to more than 90 countries and more than doubled its forecast production capacity for the year. “We have now scaled the manufacturing capacity up to 3 billion doses in 2021, and more than 40% of these doses are expected to go to middle- and low-income countries,” Sahin said. Waiving patents would not ease supply shortages in the coming months, he said, citing the complexity of producing the mRNA-based shot his company developed last year. Sahin said his company is working to further expand its manufacturing network with its own sites, such as one now planned in Singapore, and through cooperation with other manufacturers to ensure greater supply while maintaining the quality of the vaccine. But he also noted that rival manufacturers have their own shots either on the market already or in the pipeline. “We believe, together with the other vaccine developers, in the next 9 to 12 months, that there will be more than enough vaccine produced and there is absolutely no need for waiving patents,” he said. BioNTech’s estimated revenues surged to over two billion euros for the period from January to March, compared with just 28 million euros in the same period last year, after it launched the first widely used vaccine against COVID-19 together with Pfizer, which holds the market and distribution rights in much of the world. The Mainz-based company said its revenues included over 1.75 billion euros in gross profits from vaccine sales in Pfizer’s territories, and almost 200 million from sales to customers in its region. Based on current orders for some 1.8 billion doses, it expects full-year revenues of 12.4 billion euros in 2021. BioNTech shares rose by more than 7% to $196.60 in early trading on Monday on Nasdaq. The results are a significant turnaround for the company, which made a net loss of 53 million euros in the first quarter of 2020. Early last year as the pandemic began, BioNTech pivoted from researching treatments for cancer to developing a vaccine against COVID-19. Like its rival Moderna, the company’s vaccine uses mRNA technology to prime the body’s immune system to attack the virus. (With inputs from agencies)

Vaccine maker BioNTech says no need to waive patents 

Minister of State for Finance Anurag Singh Thakur on Sunday said the government has provided 175.6 million COVID-19 vaccine doses so far to states and union territories for inoculation of people of all age groups and 4.6 million doses will be supplied to them in the next three days.&nbsp;

Thakur's remarks came in response to senior Congress leader Mallikarjun Kharge's letter to Prime Minister Narendra Modi urging him to use Rs 350 billion allocated in the Union Budget to ensure free vaccine for all citizens instead of the current system of multiple pricing for various users.&nbsp;

Pune-based Serum Institute of India is supplying Covishield to the Centre for Rs 150 a dose while to states for Rs 300 a dose. Private Hospitals are getting it at double the state's price at Rs 600. &nbsp;

Whereas, Covaxin manufacturer Bharat Biotech has priced its vaccine at Rs 150 a dose for the Centre, Rs 600 a dose for state governments and Rs 1,200 a dose for private hospitals.&nbsp;

Both anti-COVID vaccines are administered in two doses. &nbsp;

Calling for free inoculation, leader of Opposition in Rajya Sabha Kharge in his letter said the Parliament had allocated Rs 350,000 million in the Union budget to ensure free vaccines for all. &nbsp;

He also urged the prime minister to immediately convene an all-party meeting to collectively forge a holistic blueprint to tackle the COVID-19 pandemic. &nbsp;

Dispelling claims of vaccine shortage in states, Thakur said 7.2 million doses are still available with states and union territories. &nbsp;

On further supply of vaccines, he said that "0.15 million doses of Sputnik V have already reached India and RDIF has also tied up with local Indian companies for bulk production." &nbsp;

In a series of tweets, the minister highlighted various measures taken by the government to increase supply of medicine and liquid medical oxygen, add more beds and distribute foreign aid to various states to fight the pandemic. &nbsp;

(With inputs from agencies)&nbsp;

Minister of State for Finance Anurag Singh Thakur on Sunday said the government has provided 175.6 million COVID-19 vaccine doses so far to states and union territories for inoculation of people of all age groups and 4.

Minister of State for Finance Anurag Singh Thakur on Sunday said the government has provided 175.6 million COVID-19 vaccine doses so far to states and union territories for inoculation of people of all age groups and 4.6 million doses will be supplied to them in the next three days. Thakur's remarks came in response to senior Congress leader Mallikarjun Kharge's letter to Prime Minister Narendra Modi urging him to use Rs 350 billion allocated in the Union Budget to ensure free vaccine for all citizens instead of the current system of multiple pricing for various users. Pune-based Serum Institute of India is supplying Covishield to the Centre for Rs 150 a dose while to states for Rs 300 a dose. Private Hospitals are getting it at double the state's price at Rs 600. Whereas, Covaxin manufacturer Bharat Biotech has priced its vaccine at Rs 150 a dose for the Centre, Rs 600 a dose for state governments and Rs 1,200 a dose for private hospitals. Both anti-COVID vaccines are administered in two doses. Calling for free inoculation, leader of Opposition in Rajya Sabha Kharge in his letter said the Parliament had allocated Rs 350,000 million in the Union budget to ensure free vaccines for all. He also urged the prime minister to immediately convene an all-party meeting to collectively forge a holistic blueprint to tackle the COVID-19 pandemic. Dispelling claims of vaccine shortage in states, Thakur said 7.2 million doses are still available with states and union territories. On further supply of vaccines, he said that "0.15 million doses of Sputnik V have already reached India and RDIF has also tied up with local Indian companies for bulk production." In a series of tweets, the minister highlighted various measures taken by the government to increase supply of medicine and liquid medical oxygen, add more beds and distribute foreign aid to various states to fight the pandemic. (With inputs from agencies)

175.6 million free vaccine doses provided to states: MoS Anurag Thakur 

vaccine

Vaccine, News on Vaccine, stories on Vaccine, articles on Vaccine, Vaccine stories at Wion, Vaccine news, Vaccine latest news